

FORM PCT-100  
(REV. 10-94)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

AUTOMATIC SEQUENCE NUMBER

2026-4269US1

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/529206

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371INTERNATIONAL APPLICATION NO.  
PCT/US98/19609INTERNATIONAL FILING DATE  
21 September 1998 (21.09.98)PRIORITY DATE CLAIMED  
08 October 1997 (08.10.97)TITLE OF INVENTION  
NOVEL HUMAN CANCER ANTIGEN NY ESO-1/CAG-3 AND GENE ENCODING SAMEAPPLICANT(S) FOR DO/EO/US  
Rong Fu WANG, et al

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau)
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired
  - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (Unsigned)
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: - Copy of the first page of the published international application No. WO 99/18206  
- Copy of the International Preliminary Examination Report  
- Copy of Response to Invitation to Furnish Nucleotide and/or Amino Acid Sequence Listing, with computer readable copy of the sequence listing in ASCII format

09/529206

INTERNATIONAL APPLICATION NO  
PCT/US98/19609NATIONAL PRIORITY NUMBER  
2026-4269US117 ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):

Search Report has been prepared by the EPO or JPO ..... \$840.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) ..... \$670.00

No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) ..... \$690.00

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$970.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) ..... \$96.00

## CALCULATIONS PTO USE ONLY

840.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$ 840.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS NUMBER FILED NUMBER EXTRA RATE

Total claims 348 -20 = 328 X\$18.00

Independent claims 17 -3 = 14 X\$78.00

MULTIPLE DEPENDENT CLAIM(S) (if applicable) +\$260.00

TOTAL OF ABOVE CALCULATIONS =

\$ 8,096.00

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).

\$

SUBTOTAL =

\$ 8,096.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

TOTAL NATIONAL FEE =

\$ 8,096.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

\$

TOTAL FEES ENCLOSED =

\$ 8,096.00

Amount to be:

refunded \$

charged \$

a. ☒ A check in the amount of \$ 8,096.00 to cover the above fees is enclosed.b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 13-4500. A duplicate copy of this sheet is enclosed.

Order No. 2026-4269US1

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO

William S. Feiler

Morgan &amp; Finnegan, L.L.P.

345 Park Avenue

New York, New York 10154

Telephone No. (212) 758-4800

Facsimile No. (212) 751-6849



SIGNATURE

William S. Feiler

NAME

26,728

REGISTRATION NUMBER

PATENT

Docket No.: 2026-4269PC

IN THE EUROPEAN PATENT OFFICE (ISA/EP)

Applicant : The Government of the United States of America, as  
represented by the Secretary, Department of Health and Human  
Services et al

International  
Application No.: PCT/US98/19609

International  
Filing Date : 21 September 1998 (21.09.1998)

For : **NOVEL HUMAN CANCER ANTIGEN  
ESO-1/CAG-3 AND GENE ENCODING SAME**

VIA FACSIMILE  
ORIGINAL AND COMPUTER READABLE DISK VIA DHL COURIER

International Searching Authority  
European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Netherlands

Attn: Mirella Deleye-Milani

RESPONSE TO INVITATION TO FURNISH  
NUCLEOTIDE AND/OR AMINO ACID SEQUENCE LISTING

In response to the Invitation to Furnish Nucleotide and/or Amino Acid  
Sequence Listing dated 02 December 1998, Applicants have provided herein:

- 1) A paper copy of a Sequence Listing; sheets numbered  
consecutively from 1 to 25 under WIPO Standard ST.23 (Exhibit A);
- 2) A computer readable copy of the sequence listing in ASCII  
format under WIPO Standard ST.23 (Exhibit B);
- 3) Replacement sheet 32/1 inserting Sequence Nos. 105 and  
106(Exhibit C);

4) A Statement in compliance with Rule 27a(2) and 27a(3) EPC and 37 C.F.R. §1.821(f) and (g) indicating the information recorded in computer readable form is identical to the written sequence listing and that the sequence listing does not include matter which goes beyond the disclosure in the international application as filed (Exhibit D).

Please insert the paper copy of the sequence listing and replacement sheet 32/1 at the appropriate location in the above-identified patent application.

Applicants are of the belief that they have fully complied with WIPO Standard ST.23 for sequence listings. Should there be any outstanding matters relating to this submission, please contact the Applicants' Agent of Record.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: 26 January 1999

By:

  
Agent for Applicants  
Kathryn M. Brown

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, New York 10154  
(212)758-4800 TELEPHONE  
(212)751-6849 (FAX)

## SEQUENCE LISTING

<110> The Government of the United States of America as

<120> Novel Human Cancer Antigen NY ESO-1/CAG-3 and Gene  
Encoding Same

<130> 20264269PC

<140> PCT/US98/19609

<141> 1998-09-21

<150> US60/061,428

<151> 1997-10-08

<160> 106

<170> PatentIn Ver. 2.0

<210> 1

<211> 805

<212> DNA

<213> Homo sapiens

<400> 1

agcagggggct gctgtgtgta ccgagaatac gagaataacct cgtgggccct gaccttctct 60

ctgagagccg ggcagaggct ccggagccat gcaggccgaa ggcgggggca caggggggtc 120

gacgggcat gctgatggcc caggaggccc tggcattcct gatggcccag ggggcaatgc 180

tggcgggcca ggagaggcgg gtgccacggg cggcagagggt ccccggggcg cagggggcagc 240

aagggcctcg gggccgggag gaggcgcccc gcggggctcg catggcgcg cggtctcagg 300

gctgaatgga tgctgcagat gcggggccag ggggcccag agccgcctgc ttgagttcta 360

cctcgccatg cttttcgaga caccatgga agcagagctg gcccgcagga gcctggccca 420

ggatgcccc cgccttccc tgccaggggt gcttctgaag gaggttcactg tgtccggcaa 480

catactgact atccgactga ctgctgcaga ccaccgcaa ctgcagctct ccatcagctc 540

ctgtctccag cagctttccc tgttgatgtg gatcacgag tgctttctgc ccgtgtttt 600

ggctcagcct ccctcagggc agaggcgcta agccagcct ggcgcctt cctaggtcat 660

gcctcctccc ctagggaatg gtccagcac gaggggcag ttcatgttg gggcctgatt 720

gtttgtcgt ggaggaggac ggcttacatg tttgtttctg tagaaaaaa aactgagcta 780

cgaaaaaaaa aaaaaaaaaa aaaa 805

<210> 2

<211> 540

<212> DNA

<213> Homo sapiens

<400> 2

atgcaggccg aaggccgggg cacagggggt tcgacgggag atgctgatgg ccagaggagg 60

cctggcatcc ctgatggccc agggggcaat gctggcgccc caggagaggc ggggtccacg 120

ggcggcagag gtccccgggg cgcaggggca gcaagggcct cggggccggg aggaggcgcc 180  
 ccgcgggggtc cgcattggcg cgcgggttca gggctgaatg gatgctgcag atcgggggcc 240  
 agggggccgg agagccgcct gcttgagttc tacctcgcca tgcctttcgc gacacccatg 300  
 gaagcagagc tggcccgag gagcctggcc caggatgccc caccgcttcc cgtgccaggg 360  
 gtgctttcga aggagttcac tgtgtccggc aacatactga ctatccgact gactgctgca 420  
 gaccaccggc aactgcagct ctccatcagc tcctgtctcc agcagctttc cctgttgatg 480  
 tggatcacgc agtgctttct gcccggtgtt ttgggtcagc ctccctcagg gcagaggcgc 540

<210> 3

<211> 174

<212> DNA

<213> Homo sapiens

<400> 3

atgctgatgg cccaggaggc cctggcattc ctgatggccc agggggcaat gctggcgccc 60  
 caggagaggc ggggtgccacg ggcggcagag gtccccgggg cgcaggggca gcaagggcct 120  
 cggggccggg aggaggcgcc ccgcggggtc cgcattggcg cgcgggttca gggc 174

<210> 4

<211> 180

<212> PRT

<213> Homo sapiens

<400> 4

Met	Gln	Ala	Glu	Gly	Arg	Gly	Thr	Gly	Gly	Ser	Thr	Gly	Asp	Ala	Asp
1					5					10					15
Gly	Pro	Gly	Gly	Pro	Gly	Ile	Pro	Asp	Gly	Pro	Gly	Gly	Asn	Ala	Gly
				20				25					30		
Gly	Pro	Gly	Glu	Ala	Gly	Ala	Thr	Gly	Gly	Pro	Gly	Pro	Arg	Gly	Ala
			35				40						45		
Gly	Ala	Ala	Arg	Ala	Ser	Gly	Pro	Gly	Gly	Gly	Ala	Pro	Arg	Gly	Pro
	50					55						60			
His	Gly	Gly	Ala	Ala	Ser	Gly	Leu	Asn	Gly	Cys	Cys	Arg	Cys	Gly	Ala
	65					70				75				80	
Arg	Gly	Pro	Glu	Ser	Arg	Leu	Leu	Glu	Phe	Tyr	Leu	Ala	Met	Pro	Phe
				85					90					95	
Ala	Thr	Pro	Met	Glu	Ala	Glu	Leu	Ala	Arg	Arg	Ser	Leu	Ala	Gln	Asp
			100						105					110	
Ala	Pro	Pro	Leu	Pro	Val	Pro	Gly	Val	Leu	Leu	Lys	Glu	Phe	Thr	Val
			115					120						125	

Ser Gly Asn Ile Leu Thr Ile Arg Leu Thr Ala Ala Asp His Arg Gln  
130 135 140

Leu Gln Leu Ser Ile Ser Ser Cys Leu Gln Gln Leu Ser Leu Leu Met  
145 150 155 160

Trp Ile Thr Gln Cys Phe Leu Pro Val Phe Leu Ala Gln Pro Pro Ser  
165 170 175

Gly Gln Arg Arg  
180

```
<210> 5
<211> 58
<212> PRT
<213> Homo sapiens
```

<400> 5  
Met Leu Met Ala Gln Glu Ala Leu Ala Phe Leu Met Ala Gln Gly Ala  
1 5 10 15

Met Leu Ala Ala Gln Glu Arg Arg Val Pro Arg Ala Ala Glu Val Pro  
20 25 30

Gly Ala Gln Gly Gln Gln Gly Pro Arg Gly Arg Glu Glu Ala Pro Arg  
35 40 45

Gly Val Arg Met Ala Ala Arg Leu Gln Gly  
50 55

```
<210> 6
<211> 9
<212> PRT
<213> Homo sapiens
```

<400> 6  
Ala Gln Pro Pro Ser Gly Gln Arg Arg  
1 5

```
<210> 7
<211> 9
<212> PRT
<213> Homo sapiens
```

<400> 7

Thr Pro Met Glu Ala Glu Leu Ala Arg

1 5

<210> 8

<211> 9

<212> PRT

<213> Homo sapiens

<400> 8

Pro Met Glu Ala Glu Leu Ala Arg Arg

1 5

<210> 9

<211> 9

<212> PRT

<213> Homo sapiens

<400> 9

Gly Ala Thr Gly Gly Arg Gly Pro Arg

1 5

<210> 10

<211> 9

<212> PRT

<213> Homo sapiens

<400> 10

Gly Pro Arg Gly Ala Gly Ala Ala Arg

1 5

<210> 11

<211> 9

<212> PRT

<213> Homo sapiens

<400> 11

Leu Ala Gln Pro Pro Ser Gly Gln Arg

1 5

<210> 12

<211> 9

<212> PRT

<213> Homo sapiens



[illegible]

```
<400> 13
Ile Arg Leu Thr Ala Ala Asp His Arg
  1             5
```

```
<400> 14
Ser Gly Pro Gly Gly Gly Ala Pro Arg
      1             5
```

```
<400> 15
Thr Val Ser Gly Asn Ile Leu Thr Ile Arg
  1             5             10
```

<400> 16  
Thr Ile Arg Leu Thr Ala Ala Asp His Arg  
1 5 10

5

<212> PRT  
<213> Homo sapiens

<400> 17  
Ala Thr Pro Met Glu Ala Glu Leu Ala Arg  
1 5 10

<210> 18  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 18  
Phe Leu Ala Gln Pro Pro Ser Gly Gln Arg  
1 5 10

<210> 19  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 19  
Thr Pro Met Glu Ala Glu Leu Ala Arg Arg  
1 5 10

<210> 20  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 20  
Arg Cys Gly Ala Arg Gly Pro Glu Ser Arg  
1 5 10

<210> 21  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 21  
Ala Ala Ser Gly Leu Asn Gly Cys Cys Arg  
1 5 10

<210> 27  
<211> 14  
<212> PRT  
<213> Homo sapiens

<400> 27  
Gly Ala Ala Arg Ala Ser Gly Pro Gly Gly Gly Ala Pro Arg  
1 5 10

<210> 28  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 28  
Ala Ala Arg Ala Ser Gly Pro Gly Gly Gly Ala Pro Arg  
1 5 10

<210> 29  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 29  
Ala Arg Ala Ser Gly Pro Gly Gly Gly Ala Pro Arg  
1 5 10

<210> 30  
<211> 11  
<212> PRT  
<213> Homo sapiens

<400> 30  
Arg Ala Ser Gly Pro Gly Gly Gly Ala Pro Arg  
1 5 10

<210> 31  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 31

Gly Pro Gly Gly Gly Ala Pro Arg

1

5

<210> 32

<211> 11

<212> PRT

<213> Homo sapiens

<400> 32

Ala Ser Gly Pro Gly Gly Gly Ala Pro Arg Gly

1

5

10

<210> 33

<211> 10

<212> PRT

<213> Homo sapiens

<400> 33

Ser Gly Pro Gly Gly Gly Ala Pro Arg Gly

1

5

10

<210> 34

<211> 10

<212> PRT

<213> Homo sapiens

<400> 34

Ala Ala Gly Pro Gly Gly Gly Ala Pro Arg

1

5

10

<210> 35

<211> 10

<212> PRT

<213> Homo sapiens

<400> 35

Ala Ile Gly Pro Gly Gly Gly Ala Pro Arg

1

5

10

<210> 36

<211> 10

<212> PRT

<213> Homo sapiens

<400> 36

Ala Leu Gly Pro Gly Gly Gly Ala Pro Arg  
1 5 10

<210> 37

<211> 10

<212> PRT

<213> Homo sapiens

<400> 37

Ala Val Gly Pro Gly Gly Gly Ala Pro Arg  
1 5 10

<210> 38

<211> 10

<212> PRT

<213> Homo sapiens

<400> 38

Ala Thr Gly Pro Gly Gly Gly Ala Pro Arg  
1 5 10

<210> 39

<211> 10

<212> PRT

<213> Homo sapiens

<400> 39

Ala Ser Gly Pro Gly Gly Gly Ala Pro Lys  
1 5 10

<210> 40

<211> 10

<212> PRT

<213> Homo sapiens

<400> 40

Ala Ser Gly Pro Gly Gly Gly Ala Pro His  
1 5 10

<210> 41

<211> 10

<212> PRT  
<213> Homo sapiens

<400> 41  
Thr Ser Gly Pro Gly Gly Gly Ala Pro Arg  
1 5 10

<210> 42  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 42  
Val Ser Gly Pro Gly Gly Gly Ala Pro Arg  
1 5 10

<210> 43  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 43  
Leu Ser Gly Pro Gly Gly Gly Ala Pro Arg  
1 5 10

<210> 44  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 44  
Arg Ser Gly Pro Gly Gly Gly Ala Pro Arg  
1 5 10

<210> 45  
<211> 20  
<212> PRT  
<213> Homo sapiens

<400> 45  
Arg Gly Pro Arg Gly Ala Gly Ala Ala Arg Ala Ser Gly Pro Gly Gly  
1 5 10 15

Gly Ala Pro Arg

```
<210> 50
<211> 13
<212> PRT
<213> Homo sapiens
```

<400> 50

Gly Ala Met Leu Ala Ala Gln Glu Arg Arg Val Pro Arg  
1 5 10

<210> 51

<211> 30

<212> DNA

<213> Homo sapiens

<400> 51

cctcggggcc gggaggaggc gccccgagg

30

<210> 52

<211> 30

<212> DNA

<213> Homo sapiens

<400> 52

ctggcgcccc aggagaggcg ggtgccacgg

30

<210> 53

<211> 27

<212> DNA

<213> Homo sapiens

<400> 53

gcggcccagg agaggcgggt gccacgg

27

<210> 54

<211> 11

<212> PRT

<213> Homo sapiens

<220>

<220>

<223> Xaa1 is no amino acid or one to about 10 amino  
acids, Xaa2 is Ala, Thr, Val, Leu or Arg, Xaa3 is  
Ser or conservative substitution, Xaa4 is Arg or  
Lys

<400> 54

Xaa Xaa Xaa Gly Pro Gly Gly Gly Ala Pro Xaa  
1 5 10

<210> 55



<211> 61  
<212> PRT  
<213> Homo sapiens

<400> 55  
Arg Cys Gly Ala Arg Gly Pro Glu Ser Arg Leu Leu Glu Phe Tyr Leu  
1 5 10 15  
Ala Met Pro Phe Ala Thr Pro Met Glu Ala Glu Leu Ala Arg Arg Ser  
20 25 30  
Leu Ala Gln Asp Ala Pro Pro Leu Pro Val Pro Gly Val Leu Leu Lys  
35 40 45  
Glu Phe Thr Val Ser Gly Asn Ile Leu Thr Ile Arg Leu  
50 55 60

<210> 56  
<211> 25  
<212> PRT  
<213> Homo sapiens

<400> 56  
Met Leu Met Ala Gln Glu Ala Leu Ala Phe Leu Met Ala Gln Gly Ala  
1 5 10 15  
Met Leu Ala Ala Gln Glu Arg Arg Val  
20 25

<210> 57  
<211> 15  
<212> PRT  
<213> Homo sapiens

<400> 57  
Ala Gly Arg Leu Tyr Leu Pro Leu Pro Pro Val Pro Val Leu Leu  
1 5 10 15

<210> 58  
<211> 24  
<212> PRT  
<213> Homo sapiens

<400> 58  
Gly Gly Pro Leu Leu Glu Phe Leu Met Pro Thr Leu Ala Arg Ser Leu

1

5

10

15

Ala Ala Leu Pro Leu Glu Gly Leu

20

<210> 59

<211> 11

&lt;212&gt; PRT

<213> Homo sapiens

&lt;400&gt; 59

Met Glu Ala Leu Phe Leu Met Gln Met Ala Val

1

5

10

<210> 60

<211> 48

<212> PRT

<213> Homo sapiens

<400> 60

Gln Ala Ala Ala Thr Gly Gly Asp Ala Arg Gln Leu Val Gly Tyr Leu

1

5

10

15

Val Ser Gln Ser Gly Leu Pro Leu Asp Thr Ser Ala Leu Gln Ala Gln

20

25

30

Leu Arg Glu Thr Leu Pro Pro His Met Val Pro Val Val Leu Leu Gln

35

40

45

<210> 61

&lt;211&gt; 64

<212> PRT

<213> Homo sapiens

<400> 61

Gln Ala Gly Val Ala Gly Pro Ala Ala Ala Leu Leu Glu Phe Thr Leu

1

5

10

15

Asn Met Leu Pro Trp Lys Thr Ala Val Gly Asp Phe Leu Ala Ser Thr

20

25

30

Arg Leu Ser Leu Ala Asp Val Ala Ala His Leu Pro Leu Val Gln His



Leu Pro Val Pro Gly Val Leu Leu Lys  
1 5

<210> 66  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 66  
Gly Val Leu Leu Lys Glu Phe Thr Val  
1 5

<210> 67  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 67  
Asn Ile Leu Thr Ile Arg Leu Thr Ala  
1 5

<210> 68  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 68  
Trp Ile Thr Gln Cys Phe Leu Pro Val  
1 5

<210> 69  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 69  
Thr Val Ser Gly Asn Ile Leu Thr Ile  
1 5

<210> 70  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 70

Leu Gln Gln Leu Ser Leu Leu Met Trp

1

5

<210> 71

<211> 9

<212> PRT

<213> Homo sapiens

<400> 71

Leu Met Trp Ile Thr Gln Cys Phe Leu

1

5

<210> 72

<211> 9

<212> PRT

<213> Homo sapiens

<400> 72

Leu Leu Met Trp Ile Thr Gln Cys Phe

1

5

<210> 73

<211> 9

<212> PRT

<213> Homo sapiens

<400> 73

Ile Leu Thr Ile Arg Leu Thr Ala Ala

1

5

<210> 74

<211> 9

<212> PRT

<213> Homo sapiens

<400> 74

Ser Ile Ser Ser Cys Leu Gln Gln Leu

1

5

<210> 75

<211> 9

<212> PRT

<213> Homo sapiens

<400> 75

Leu Gln Leu Ser Ile Ser Ser Cys Leu

1

5

<210> 76

<211> 9

<212> PRT

<213> Homo sapiens

<400> 76

Cys Leu Gln Gln Leu Ser Leu Leu Met

1

5

<210> 77

<211> 9

<212> PRT

<213> Homo sapiens

<400> 77

Ala Gln Asp Ala Pro Pro Leu Pro Val

1

5

<210> 78

<211> 9

<212> PRT

<213> Homo sapiens

<400> 78

Gln Cys Phe Leu Pro Val Phe Leu Ala

1

5

<210> 79

<211> 9

<212> PRT

<213> Homo sapiens

<400> 79

Arg Gln Leu Gln Leu Ser Ile Ser Ser

1

5

<210> 80

<211> 9

<212> PRT

<213> Homo sapiens

<400> 80

Ser Leu Ala Gln Asp Ala Pro Pro Leu

1

5

<210> 81

<211> 9

<212> PRT

<213> Homo sapiens

<400> 81

Asn Gly Cys Cys Arg Cys Gly Ala Arg

1

5

<210> 82

<211> 9

<212> PRT

<213> Homo sapiens

<400> 82

Thr Ile Arg Leu Thr Ala Ala Asp His

1

5

<210> 83

<211> 9

<212> PRT

<213> Homo sapiens

<400> 83

Ala Ser Gly Leu Asn Gly Cys Cys Arg

1

5

<210> 84

<211> 10

<212> PRT

<213> Homo sapiens

<400> 84

Thr Val Ser Gly Asn Ile Leu Thr Ile Arg

1

5

10


























Cys Leu Gln Gln Leu Ser Leu Leu Met Trp  
 1 5 10

<210> 90  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 90  
 Asn Ile Leu Thr Ile Arg Leu Thr Ala Ala  
 1 5 10

<210> 91  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 91  
 Phe Thr Val Ser Gly Asn Ile Leu Thr Ile  
 1 5 10

<210> 92  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 92  
 Leu Leu Met Trp Ile Thr Gln Cys Phe Leu  
 1 5 10

<210> 93  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 93  
 Leu Leu Glu Phe Tyr Leu Ala Met Pro Phe  
 1 5 10

<210> 94  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens



<212> PRT  
<213> Homo sapiens

<400> 99  
Arg Gln Leu Gln Leu Ser Ile Ser Ser Cys  
1 5 10

<210> 100  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 100  
Gly Leu Gly Cys Cys Arg Cys Gly Ala  
1 5

<210> 101  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 101  
Tyr Leu Ala Met Pro Phe Ala Thr Pro Met  
1 5 10

<210> 102  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 102  
Gly Ile Pro Asp Gly Pro Gly Gly Asn Ala  
1 5 10

<210> 103  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 103  
Gln Leu Gln Leu Ser Ile Ser Ser Cys Leu  
1 5 10

<210> 104  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 104  
Leu Thr Ile Arg Leu Thr Ala Ala Asp His  
1 5 10

<210> 105  
<211> 23  
<212> DNA  
<213> Homo sapiens

<400> 105  
gcggcttcag ggctgaatgg atg 23

<210> 106  
<211> 22  
<212> DNA  
<213> Homo sapiens

<400> 106  
aagccgtcct cctccagcga ca 22

000190 900202560

MORGAN & FINNEGAN, L.L.P.  
345 PARK AVENUE  
NEW YORK, NEW YORK 10154-0053

Protect OFF

Protect ON

CLIENT REF:

Morgan & Finnegan, L.L.P.  
345 Park Ave., N.Y. N.Y. 10154  
(212) 738-4800

DOCKET NO.:

202a-4269PC

FORMAT:

ASCI

APPLICANT:

The Government Of The United States Of

America

Novel Human Cancer Angigen NY ESG.

UCAG-1 And Gene Encoding Same

1995-01-25

IBM PC Compatible, PC-DOS/MS-DOS

1994-09-21

PCT/US98/19609

200533175

M&F FILE (blue)

SEQUENCE LISTING

TITLE:

DATE RECORDED:

COMPUTER/OS

FILING DATE:

SERIAL NO.:

DHL MAIL NO.:

**Reverse Transcriptase-PCR**

Total RNA was extracted from tumor cell lines as described above. Five hundred nanograms of total RNA was used for conversion of RNA to cDNA by avian myeloblastosis virus (AMV) reverse transcriptase. cDNA was then amplified by  
5 PCR using the ESO-P2 (5'-GCGGCTTCAGGGCTGAATGGATG) (SEQ. ID No. 105) and ESO-P5 (5'-AAGCCGCTCCTCCTCCAGCGACA) (SEQ. ID No. 106) primers and One-Step RT-PCT system (Life Technologies). PCR products were amplified under denaturation conditions at 94°C for 30 s, annealing at 55° for 30 s, extension at 72° for 3 min for 40 cycles, and final elongation at 72° for 10 min. PCR products  
10 were analyzed on a 3% agarose gel.

**Cytotoxic lysis assays**

Cytolytic assay was done as previously described (Kawakami, Y et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:6458-62). Briefly, the target cells were labeled with chromium for 90 min. After washing three times, the cells were incubated with  
15 peptides at a concentration of 1 µg/ml for 90 min. The cells were washed again, counted, and then mixed with TIL586 or CTL clone 5 at the indicated ratio of effector : targets (E : T). Chromium release was measured after 4 h incubation. The peptides were synthesized by a solid-phase method using a peptide synthesizer (Model AMS 422, Gilson Co., Inc., Worthington, OH). Some peptides were purified by HPLC and  
20 had greater than 98% in purity. The mass of some peptides was confirmed by mass spectrometry analysis. For titration of the CAG-3 peptide recognized by TIL586, 586EBV B cells were incubated with various concentrations of the purified CAG-3 peptide or portion thereof. Percentage of specific lysis was determined from the equation (A-B)/(C-B) X 100 where A is lysis of 586EBV B cells by TIL586 or clone 5  
25 in the presence of a peptide, B is spontaneous release from 586EBV B cells in presence of the same peptide but in the absence of effector cells, and C is the maximum chromium release. Cold target inhibition of cytolysis was performed using <sup>51</sup>Cr-labeled 586mel or 624mel cells as "hot" targets and 586EBV B and T2 cells pulsed with peptides as "cold" targets.

PATENT

Docket No.: 2026-4269PC

IN THE EUROPEAN PATENT OFFICE (ISA/EP)

Applicant : The Government of the United States of America, as  
represented by the Secretary, Department of Health and Human  
Services et al

International  
Application No.: PCT/US98/19609

International  
Filing Date : 21 September 1998 (21.09.1998)

For : **NOVEL HUMAN CANCER ANTIGEN  
ESO-1/CAG-3 AND GENE ENCODING SAME**

VIA FACSIMILE  
ORIGINAL VIA DHL COURIER

International Searching Authority  
European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Netherlands

Attn: Mirella Deleye-Milani

STATEMENT UNDER RULE 27A(2) AND Rule 27a(3)  
AND 37 C.F.R. §1.821(f) and (g)

In compliance with Rule 27a(2) EPC and 37 C.F.R. §1.821(f),  
Applicants submit that the information recorded on the electronic data carrier is  
identical to the written sequence listing; and in compliance with Rule 27a(3) EPC and  
37 C.F.R. §1.821(g), that the sequence listing documents do not include matter which  
goes beyond the content of the PCT application as filed.

Applicants believe that this statement complies with WIPO Standard  
ST.23.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: 26 January 1999

By:

  
Agent for Applicants  
Kathryn M. Brown

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, New York 10154  
(212)758-4800 TELEPHONE  
(212)751-6849 (FAX)

005238-051300



PATENT

DOCKET NO. 2026-4269US1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S) : Wang, Rong-Fu

U.S. NATIONAL APPLICATION  
OF INTERNATIONAL  
APPLICATION NO. :

PCT/US98/19609

INTERNATIONAL FILING  
DATE :

21 September 1998

PRIORITY DATE :

8 October 1997

FOR :

NOVEL HUMAN CANCER ANTIGEN  
NY-ESO-1/CAG-3 AND GENE ENCODING  
SAME

GROUP ART UNIT :

To be assigned

EXAMINER :

To be assigned

Assistant Commissioner for Patents  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

Prior to examination of the U.S. National Application filed under 35 U.S.C.

§371, please enter the Amendment under Article 34 and amend the following claims without  
prejudice:

**In the claims:**

6. (Amended) A cancer peptide, portion or derivative thereof according  
to any one of claims [claim] 2-4 or 5 wherein the cancer peptide is immunologically  
recognized by HLA restricted cytotoxic T lymphocytes.

534128\_1

09/529206-001200

7. (Amended) A cancer peptide, portion or derivative thereof according to any one of claims [claim] 2-4 or 5 wherein the cytotoxic T lymphocytes are MHC class I restricted.

8. (Amended) A cancer peptide, portion or derivative thereof according to any one of claims 2-4 or 5 [claim 2-6 or 7] wherein the cancer peptide is derived from a cancer selected from the group consisting of: a non-Hodgkins lymphoma, leukemia, Hodgkins lymphoma, lung cancer, liver cancer, metastases, melanoma, adenocarcinoma, thymoma, colon cancer, uterine cancer, breast cancer, prostate cancer, ovarian cancer, cervical cancer, bladder cancer, kidney cancer, pancreatic cancer and sarcoma.

9. (Amended) A cancer peptide, portion or derivative thereof according to any one of claims 2-4 or 5 [claim 2-7 or 8] wherein the cancer peptide or portion thereof is present on primary breast tumor isolates and melanoma cells.

28. (Amended) A pharmaceutical composition comprising at least one cancer peptide according to any one of claims 2-[24,] 5, 10- 26 or 27 and a pharmaceutically acceptable carrier.

30. (Amended) A immunogen comprising the cancer peptide according to any one of claims 2-[24,] 5, 10- 26 or 27 alone or in combination with at least one immunostimulatory molecule, said immunogen elicits antigen specific cytotoxic T lymphocytes.

39. (Amended) A recombinant expression vector comprising the nucleic acid sequence according to any one of claims 32-37 or 38.

42. (Amended) An oligonucleotide consisting of a nucleic acid sequence complementary to the nucleic acid sequence according to any one of claims 32-37 or 38.

43. (Amended) A recombinant virus comprising a recombinant virus which has incorporated into a viral genome or portion thereof the nucleic acid sequence according to any one of claims 32-37 or 38.

48. (Amended) A host organism transformed or transfected with the recombinant virus according to claim 43[-46 or 47].

59. (Amended) A method of detecting the cancer peptide or portion thereof according to any one of claims 2-[24,] 5, 10- 26 or 27 in a biological sample comprising:

- a. contacting the sample with antibodies specific for said cancer peptide under conditions to form an immune complex, and
- b. detecting the presence of the immune complex.

60. (Amended) A method of preventing or inhibiting cancer in a mammal comprising: administering to the mammal an effective amount of the cancer peptide, or portion thereof according to any one of claims 2-[24,] 5, 10- 26 or 27, alone or in combination with an HLA molecule, said amount is effective in preventing or inhibiting the cancer in the mammal.

61. (Amended) A method of inhibiting melanoma in a mammal comprising:

- a. exposing T lymphocytes *in vitro* to a cancer peptide, tumor

antigen or portion thereof according to any one of claims 2-  
[24,] 5, 10- 26 or 27, alone or in combination with an MHC  
molecule for a time sufficient to elicit cancer peptide specific T  
lymphocytes;

- b. administering the cancer peptide specific T lymphocytes to the  
mammal in an amount sufficient to inhibit the melanoma.

62. (Amended) A method of preventing or inhibiting cancer in a mammal  
comprising: administering to the mammal an effective amount of the cancer peptide  
according to any one of claims 2-[24,] 5, 10- 26 or 27 alone, or in combination with an HLA  
molecule, said amount is effective in preventing or inhibiting cancer in a mammal.

63. (Amended) A method of preventing or inhibiting cancer in a mammal  
comprising administering to the mammal an effective amount of a recombinant virus  
according to claim[s] 43[-46 or 47] alone or in combination with an exogenous  
immunostimulatory molecule said amount is effective in preventing or inhibiting the cancer.

65. (Amended) A pharmaceutical composition comprising the  
recombinant virus according to claim[s] 43[-46 or 47] alone or in combination with an  
exogenous immunostimulatory molecule, chemotherapy drug, antibiotic, antifungal drug,  
antiviral drug or combination thereof and a pharmaceutically acceptable carrier.

67. (Amended) A cancer antigen specific human cytotoxic T lymphocyte  
elicited by the cancer peptide according to any one of claims 2-[24,] 5, 10- 26 or 27.

REMARKS


No new matter is added by this amendment. Entry thereof is respectfully requested. The preliminary amendment is to correct multiple dependency in certain claims. The amendment should in no way be construed as an action in regard to enablement or patentability issues.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated:

April 7, 2000

  
Kathryn M. Brown  
Agent for Applicants  
Reg. No. 34,556

Mailing Address:

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, New York 10154  
(212) 758-4800 (TELEPHONE)  
(212) 751-6849 (FACSIMILE)

002290, 002290, 002290

**NOVEL HUMAN CANCER ANTIGEN****NY ESO-1/CAG-3 AND GENE ENCODING SAME****Field of the Invention**

5           The present invention relates to the area of cancer diagnostics and therapeutics including a cancer vaccine. More specifically, the invention relates to the isolation and purification of a novel human cancer peptide, NY ESO-1/CAG-3, epitopes, and analogs thereof and DNA sequence encoding the cancer peptide or portion thereof. The invention further relates to methods of detecting, diagnosing and  
10       treating cancer and precancer in an individual.

**Background of the Invention**

          The adoptive transfer of tumor infiltrating lymphocytes (TIL) can mediate tumor regression in patients with metastatic melanoma, suggesting that tumor  
15       rejection antigens recognized by T cells exist on these tumor cells. The availability of such T cells has made it possible to clone and sequence the genes that encode human melanoma antigens. The antigens identified so far from human melanoma can be divided into two classes based on their expression pattern. The antigens of the first class are encoded by genes that are expressed only in tumor and testis, but not other  
20       normal human tissues. MAGE1, MAGE3, GAGE and BAGE are examples of this class. The second class of antigens represents differentiation antigens encoded by genes that are expressed only in melanocytes, melanomas, and normal retina. MART-1/Melan-A, gp100 and tyrosinase are examples of this class. All these antigens are nonmutated self proteins. However, several mutated antigens were also identified to  
25       be recognized by T cells, including CDK 4, B-catenin and Mum-1. Identification of the antigenic epitopes recognized by T cells derived from the corresponding gene products is important not only for understanding the mechanism of immune response to self antigens, but also for developing new, effective immunotherapeutic strategies

- 2 -

with these antigens or synthetic peptides for the treatment of patients with cancer.

Previous studies showed that the infusion of TIL586 plus IL-2 into the autologous patient with melanoma resulted in the objective regression of metastases. More recently, the gene, tyrosinase-related protein 1 (TRP-1 or gp75) was cloned which encodes the tumor antigen recognized by TIL586 in association with HLA-A31. Interestingly, the gene product, gp75, was originally identified as an antigen recognized by IgG antibodies in the serum from a patient with metastatic melanoma. The gene was found to be expressed only in melanoma, normal melanocyte cell lines, and retina, but not in other normal tissues tested. Therefore, this gene is a member of the second class of antigens including MART-1/Melan-A, gp100 and tyrosinase.

Wang, R. F. et al J. Exp. Med. Vol. 183, pp. 1131-1140 (1996) report on the identification of a cancer peptide encoded from an alternative open reading frame sequence within the TRP-1 gene which is specifically recognized by cloned TIL 586 cells. Wang, R.F. et al J. Exp. Med. Vol 184, pp. 2207-2216 (1996) identified a second tumor antigen, TRP-2, recognized by a HLA-A31-restricted CTL clone derived from the TIL 586 cell line.

The present invention is the identification and isolation of novel tumor antigens distinct from TRP-1 and TRP-2 which are recognized by CTL clones derived from the TIL 586 cell line. The cancer peptides of the invention are useful as an immunogen and vaccine to inhibit or prevent cancer in a mammal and as a diagnostic agent to detect cancer or precancer.

### **Summary of the Invention**

One object of the present invention is to provide a novel peptide and portions thereof recognized as a cancer antigen by T lymphocytes.

The tumor antigen of the present invention and the antigenic cancer peptides of the tumor antigen are encoded by all or a portion of the NY ESO-1/CAG-3 (term used interchangeably herein with CAG-3) gene (SEQ ID NO:1). CAG-3 is a

- 3 -

new and potent tumor antigen capable of eliciting an antigen specific immune response by T cells.

One aspect of the invention is cancer peptides encoded by various open reading frames of the CAG-3 gene, or variants thereof, which are useful as a cancer vaccine capable of protecting the recipient from development of cancer. The present invention also relates to a method of administering the cancer vaccine in an effective amount to inhibit or prevent cancers or inhibit the growth of cells expressing the CAG-3 gene product. The CAG-3 gene product may be derived from a normal open reading frames from (ORF-1) or derived from an alternative open reading frame from SEQ. ID

NO: 1.

Another aspect of the present invention is a pharmaceutical composition comprising a CAG-3 protein, peptide or antigenic cancer epitope thereof alone or in combination with one or more immunostimulatory molecules. The pharmaceutical composition comprising at least one CAG-3 epitope, or combination of epitopes stimulate CAG-3 antigen specific T-cells to elicit an immunogenic response against tumors and cancers. The cancer peptide or antigenic cancer epitope thereof may be provided as an immunogen or as a vaccine for prevention or treatment of cancer. The pharmaceutical composition is useful in methods of treating or preventing cancer in a mammal. In the method of treatment, the pharmaceutical composition is administered to the mammal in an amount effective in preventing or inhibiting the cancer in the mammal.

Another object of the present invention is a method of generating CAG-3 cancer peptides and the antigenic cancer epitope within the peptide by translation of DNA sequence encoding same from a CAG-3 gene.

A further aspect of the invention is the DNA or RNA sequence that encodes a CAG-3 cancer peptide or portion thereof and the use of the DNA or RNA sequence in methods of producing the cancer peptide or portions thereof. The invention further provides oligonucleotides of the DNA or RNA sequence for use as



- 4 -

probes or primers.

The present invention further provides vectors comprising DNA sequence encoding a CAG-3 cancer peptide or portions thereof alone or in combination with a second DNA sequence encoding at least one immunostimulatory molecule.

The invention also provides host cells transfected or transduced with a vector comprising DNA sequence encoding a CAG-3 cancer peptide or portions thereof alone or in combination with a second DNA sequence encoding at least one immunostimulatory molecule. The vectors and host cells may serve as vaccines in which expression of a cancer peptides results in the stimulation of tumor antigen specific T lymphocytes in a mammal immunized with the vaccine.

The invention provides a method of diagnosis of cancer or precancer in a mammal by detection of a CAG-3 cancer peptide or portions thereof.

It is still another object of the invention to provide a method for diagnosing human preneoplastic and neoplastic cells and tissues. In accordance with the invention, the method comprises isolating cells, tissues or extracts thereof from a human and detecting the DNA sequence, RNA sequence or portion thereof encoding a CAG-3 cancer peptide or portions thereof or detecting the CAG-3 cancer peptide or portions thereof expressed by the DNA sequence or RNA sequence, wherein detection of/or increase in the DNA sequence, RNA sequence or expression product is indicative of preneoplasia and neoplasia.

Still another object of the invention is to provide a transgenic animal which has incorporated into its genome one or more copies of the DNA sequence encoding a CAG-3 cancer peptide or portion thereof. The incorporation of the DNA sequence results in expression or overexpression of the CAG-3 cancer peptide. Such transgenic animals are useful for screening of therapeutic agents useful in treating cancer.

The invention also encompasses antisense oligonucleotides which

- 5 -

specifically target and bind to the open reading frame nucleic acid sequence or portion thereof of CAG-3 and inhibit the expression of the cancer peptide or tumor antigen without adversely affecting the expression of the normal protein from the same gene.

- Still another aspect of the invention are monoclonal and polyclonal antibodies reactive with the CAG-3 cancer peptide and antigenic cancer epitope thereof, for use in diagnostic and detection assays. The monoclonal and polyclonal antibodies may be provided in the form of a kit alone, or along with other reagents commonly used in diagnostic and detection assays.

#### **Brief Description of the Figures**

- These and other objects, features, and many of the attendant advantages of the invention will be better understood upon a reading of the following detailed description when considered in connection with the accompanying drawings wherein:

- Figure 1A through 1C show the GM-CSF release of CTLs cloned from TIL586 in response to stimulation by various antigen expressing cells. CTL clones were isolated by the limiting dilution method and were further expanded. 1A. GM-CSF release by CTL clone 4 was measured after coculturing with different target cells. 1B and 1C. In a separate experiment, GM-CSF release by CTL clones 5 and 10 was determined after coculturing with different stimulators. NHEM680 is a HLA-A31-positive normal melanocyte cell line, 397mel is an HLA-A31-positive normal melanocyte cell line, 397mel is an HLA-A31-negative melanoma cell line and 586mel is an HLA-A31-positive melanoma cell line.

Figure 2 shows the GM-CSF release of CTL clone 5 and CTL clone 10 in response to stimulation by various known tumor antigens.

- Figure 3A. Nucleotide and amino acid sequence of NY-ESO-1. Figure 3A. Numbering of nucleotide sequence of *NY-ESO-1* starts from the first nucleotide in the 5' untranslated region. ORF1 represents the gene product of *NY-ESO-1*, and ORF2 represents a 58-amino acid gene product translated from the ORF2. Antigenic peptides recognized by CTL clone 2 and 5 are boxed. In addition, a peptide poorly

- 6 -

recognized by CTL clone 5 is underlined. Figure 3B. Sequence alignment of the ESO-ORF1 protein with enterobactin synthetase component F (accession g250614) and tegument protein of herpes simplex virus type 1 (accession p10220). The residues are numbered with the first start site representing the first amino acid. Alignment of the ESO-ORF2 and glutamate dehydrogenase (accession g1942184) was also shown. The conserved amino acid substitution is indicated by the + symbol.

Figure 4 shows that COS-7 cells transfected with CAG-3 and an HLA-A31 molecule are recognized by CTL clone 5 lymphocytes.

Figure 5A-5C. Characterization of the 9-mer ESO9-54 and 10-mer ESO10-53 derived from the normal open reading frame. Figure 5A. 586EBV or 1510EBV B cells were pulsed with ESO10-53 and ESO9-54 peptides at different concentrations for 120 min. After two washes with AIM-V medium with 120 IU IL-2, CTL clone 5 ( $1 \times 10^5$ /well) was added and incubated for 18 to 24 h. GM-CSF release by CTL clone 5 was determined by ELISA. Figure 5B. 586mel cells were lysed by CTL clone 5, but 397mel cells were not lysed by CTL clone 5 at different E:T ratios. Figure 5C. 586EBV and 1510EBV B cells were labeled with chromium overnight. The ESO10-53 peptide was then pulsed on the chromium-labeled 586EBV, 1510EBV, and T2 cells for 120 min. An irrelevant peptide containing an HLA-A31 peptide-binding motif was also pulsed on chromium-labeled 586EBV, 1510EBV B cells as negative controls. After peptide incubation and two washes, cytolysis of target cells by CTL clone 5 was determined in a 4-h chromium release assay. T2 pulsed with the ESO10-53 peptide was used for the specificity control.

Figures 6A-6H. CTL clones 2 and 14 recognize the NY-ESO-1 gene, but not the ESO10-53 peptide derived from the NY-ESO-1 protein. CTL clones 2, 14 and 5 recognized NY-ESO-1 when cotransfected with HLA-A31 cDNA into COS-7 (Figure 6A, C, E and G). TIL1244, which recognized TRP-2 but not NY-ESO-1, was used as a specificity control. Figures 6B, D, F and H. CTL clones 2, 5, 14, and TIL1244 recognized 586mel. However, CTL clones 2 and 14 did not recognize the

- 7 -

ESO10-53 peptide, whereas CTL clone 5 strongly recognized the ESO10-53 peptide when pulsed onto HLA-A31 positive 586EBV B cells. TIL1244 recognized the TRP197-205 peptide derived from TRP-2, 586EBV B cells alone or pulsed with the ORF3P peptide from an alternative reading frame of TRP1 were negative controls.

- 5 397mel is an HLA-A31-negative, NY-ESO-1-positive tumor line.

Figure 7A-7C. An alternative open reading frame of the *NY-ESO-1* gene and antigenic peptides recognized by CTL. Figure 7A. Identification of antigenic peptides from the ORF2. Thirty peptides were synthesized based on all potential ORFs and screened. Representative data are shown here. Seven peptides derived from

- 10 ORF2 (see Fig. 3A) were pulsed on HLA-A31-positive 1510EBV B cells and tested for T cell recognition based on GM-CSF release. 1510EBV alone was used as a negative control. Figure 7B. 1510EBV B cells were labeled with chromium for 2 h. The ESORF2-10-18 peptide was then pulsed on the chromium-labeled 1500EBV (solid square) and HLA-A31-negative 1102EBV (open circle) at different
- 15 concentrations. 1510EBV pulsed with ESO10-53, which was recognized by CTL clone 5, was used for the specificity control (solid triangle). After peptide incubation and three washes, cytolysis of target cells by CTL-clone 2 was determined in a 4-h chromium release assay at an E:T ratio of 20:1. Figure 7C. Several tumor lines and fresh breast tumors were tested for recognition by CTL clone 2 to determine whether
- 20 the ORF2 is translated in different tumors. 1510EBV B cells pulsed with ESO10-53, ORF2-10-18, or alone were included to evaluate the reactivity and specificity of CTL clone 2 and 5. Expression of HLA-A31 on the tumor cells is indicated.

#### **Detailed Description of the Invention**

- 25 The present invention encompasses cancer peptides, tumor antigen and portion, derivatives or variants thereof which are immunologically recognized by T lymphocytes of the immune system. The present invention further encompasses the antigenic cancer epitope(s) which are contained in the cancer peptides or tumor antigen. The antigenic cancer epitope specifically causes a cellular mediated immune

- 8 -

response by interaction with T cells of the immune system. This interaction between the antigenic cancer epitope and the T cells causes the T cells to respond against, and prevent, eliminate or reduce the cancer in a mammal, including humans.

5 The cancer peptide and portions thereof are characteristically absent from or present in very low levels from normal cells from the majority of tissue sources and are present in high levels from pre-cancer and cancer cells. Expression of the cancer peptide at high levels correlates with transformation of normal cells to a pre-cancer or cancer cell.

10 The cancer peptides of the present invention form part of, or are derived from, cancers including but not limited to primary or metastatic melanoma, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, non-Hodgkin's lymphoma, Hodgkins lymphoma, leukemias, uterine cancer, cervical cancer, bladder cancer, kidney cancer and adenocarcinomas such as breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, thyroid cancer and the like.

15 The term melanoma includes, but is not limited to, melanomas, metastatic melanomas, melanomas derived from either melanocytes or melanocyte related nevus cells, melanocarcinomas, melanoepitheliomas, melanosarcomas, melanoma in situ, superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentiginous melanoma, invasive melanoma or familial atypical mole  
20 and melanoma (FAM-M) syndrome.

Of particular interest are cancer peptides, fragments or derivatives thereof recognized by autologous CTL in patients with cancer, in particular melanoma. Of further interest are cancer peptides, fragments or derivatives thereof recognized by MHC (or HLA) restricted CTL, in particular MHC class I restricted CTLs.

25 The "tumor antigen" of the present invention encompasses the cancer or tumor protein and any portion or peptide of the cancer or tumor protein capable of eliciting an anti-tumor response in mammals. In one embodiment, the tumor antigen includes the full-length CAG-3 protein. In another embodiment, the tumor or cancer

antigen is about 10 amino acids in length.

"Cancer peptides" as the term is used herein, encompasses any epitope or fragment of cancer or tumor protein, which acts as a tumor antigen.

The MHC restricted T lymphocytes are useful in identifying the gene product, CAG-3, associated with cancer and pre-cancer. In one embodiment, a cancer peptide, fragment or derivative thereof of the present invention comprises antigenic cancer epitope immunologically recognized by tumor infiltrating lymphocytes (TIL) derived from a cancer tumor of a mammal. Of particular interest are antigenic cancer epitopes recognized by cancer antigen specific cytotoxic T cells (CD 8<sup>+</sup>).

In one embodiment, the cancer peptide of the present invention comprises the amino acid sequence:

MQAEGRGTGG	STGDADGPGG
PGIPDGPGGN	AGGPGEAGAT
GGPGPRGAGA	ARASGPGGGA
PRGPHGGAAS	GLNGCCRCGA
RGPE SRLLEF	YLAMPFATPM
EAELARRSLA	QDAPPLPVP
VLLKEFTVSG	NILTIRLTAA
DHRQLQLSIS	SCLQQLSLLM

WITQCFLPVF LAQPPSGQRR (SEQ. ID NO: 4) and cancer epitopes, fragments, or derivatives thereof. Also encompassed in the ambit of the invention are cancer peptides or portions thereof that share partial sequence homology with SEQ. ID NO: 4. By partial amino acid sequence homology is meant a peptide having at least 85% sequence homology with SEQ. ID NO: 4, preferably at least 95% sequence homology or greater and has the biological function of stimulating cancer antigen specific T lymphocytes. Mammalian homologs are included in the ambit of the invention including but not limited to primate and murine homologs.

In an embodiment of the present invention the cancer peptide may be

- 10 -

represented by the formula:

Xaa<sub>1</sub>, Xaa<sub>2</sub> Xaa<sub>3</sub> GPGGGAPXaa<sub>4</sub> (SEQ. ID NO: 54),

wherein Xaa<sub>1</sub> is no amino acid or one to about 10 amino acids,

preferably one to about 5 amino acids, Xaa<sub>2</sub> is Ala, Thr, Val, Leu or Arg, Xaa<sub>3</sub> is Ser  
5 or a conservative substitution such as Ala, Val, Ile, Leu, Thr and the like, Xaa<sub>4</sub> is Arg,  
Lys, preferably Arg and fragments and derivatives thereof.

In one embodiment, the cancer peptide of the present invention  
comprises the amino acid sequence:

SGPGGGAPR (SEQ. ID NO: 14).

10 In another embodiment the cancer peptide of the present invention  
comprises the amino acid sequence:

Position No.

12345678910

ASGPGGGAPR (SEQ. ID NO: 25).

15 Peptides having substitutions within a sequence ID No: 25 is  
encompassed by the present invention. In one embodiment the substitution is at  
position 1, anchor positions 2, 10 or combinations thereof. For example, cancer  
peptides of the present invention comprise the following amino acid sequences:

ASGPGGGAPK (SEQ. ID NO: 39);

20 AAGPGGGAPR (SEQ. ID NO: 34);

AIGPGGGAPR (SEQ. ID NO: 35);

ALGPGGGAPR (SEQ. ID NO: 36);

AVGPGGGAPR (SEQ. ID NO: 37);

ATGPGGGAPR (SEQ. ID NO: 38).

25 In another embodiment, a cancer peptide of the present invention  
comprises the amino acid sequence:

VSGPGGGAPR (SEQ. ID NO: 42).

Another example of a cancer peptide of the present invention comprises

- 11 -

the amino acid sequence:

TSGPGGGAPR (SEQ. ID NO: 41).

Peptides having about 1 to about 10, preferably about 1 to 5 additional amino acids at the N-terminus of SEQ. ID NOS: 14, 25, 34-38, 41 and 42 also form part of the present invention. As an example, a cancer peptide of the present invention having additional amino acids at the N-terminus comprises the amino acid sequence:

AGAARASGPGGGAPR (SEQ. ID NO: 26)

Another example of a cancer peptide of the present invention having additional amino acids at the N-terminus comprises the amino acid sequence:

RGPRGAGAARASGPGGGAPR (SEQ. ID NO: 45)

Another embodiment of the present invention is a cancer peptide comprising the amino acid sequence:

TVSGNILTIR (SEQ. ID NO: 15)

In another embodiment of the invention, the cancer peptide comprises the amino acid sequence:

MLMAQEALAF	LMAQGAMLA
QERRVPRAAE	VPGAQQQQGP
RGREEAPRGV	RMAARLQG (SEQ. ID NO: 5) and cancer

epitopes, fragments, derivatives and homologs thereof. The cancer peptide may be derived from an alternative open reading frame sequence of SEQ. ID NO: 3.

In another embodiment, the cancer peptide comprises the amino acid sequence:

AAQERRVPR (SEQ. ID NO: 46).

In one embodiment, the cancer peptide comprises the amino acid sequence:

Position No.

12345678910

LAAQERRVPR (SEQ. ID NO: 47), and cancer epitopes,



- 12 -

fragments, derivatives and homologs thereof. Also included within the ambit of the present invention are cancer peptides of SEQ. ID NO: 47 having an amino acid substitution at position 1, 2, 6, 9 or combination thereof provided the substituted peptide retains functional activity in stimulation cancer peptide specific cytotoxic T lymphocytes.

Also included within the ambit of the present invention is a cancer peptide having one to about 10 additional amino acids, at the N-terminus of SEQ. ID NO: 47, preferably one to about 5 amino acids, more preferably one to about 3 amino acids at the N-terminus of SEQ. ID NO: 47. In one embodiment, cancer peptides of the present invention comprise the amino acid sequences:

MLAAQERRVPR (SEQ. ID NO: 48);  
AMLAAQERRVPR (SEQ. ID NO: 49); and  
GAMLAQERRVPR (SEQ. ID NO: 50).

The CAG-3 cancer peptides and the antigenic cancer epitope contained within the tumor antigen of the present invention are expressed in normal testis but not in other normal tissue. The tumor antigen of the present invention present in significantly lower levels in most normal cells as compared to the elevated levels found in pre-cancer and cancer cells. Elevated expression of the tumor antigen correlates with transformation of normal cells to a pre-cancer or cancer cell. CAG-3 is expressed in a variety of cancers including melanoma, breast cancer, prostate cancer, ovarian cancer, lung cancer, thyroid cancer, bladder cancer and liver cancer.

Of further interest are CAG-3 cancer peptides, fragments or derivatives thereof recognized by MHC restricted CTL, in particular MHC class I restricted CTLs. HLA Class I restricted CTLs include but are not limited to HLA-A31, HLA-A3, HLA-A11, HLA-A33 and HLA-A68. A preferred HLA subtype recognized by the CAG-3 cancer peptides is the HLA-A31 subtype.

Another embodiment of the present invention encompasses derivatives and variants of the cancer peptides having sufficient homology to CAG-3 or epitopes

- 13 -

thereof to effectively act as cancer peptides. Such peptides may have conservative amino acid changes at one or more positions. By conservative amino acid changes is meant, an amino acid change at a particular position which is of the same type as originally present; i.e. a hydrophobic amino acid exchanged for a hydrophobic amino acid, a basic amino acid for a basic amino acid, etc. Such amino acid changes do not significantly alter the overall charge and configuration of the peptide and therefore such variants maintain or enhance the anti-cancer activity of a cancer peptide. Examples of such conservative changes are well-known to the skilled artisan and are within the scope of the present invention.

The present invention also relates to functionally equivalent variants of the CAG-3 cancer peptides. "Functionally equivalent variants" includes peptides with partial sequence homology, peptides having one or more specific conservative and/or non-conservative amino acid changes, peptide conjugates, chimeric proteins, fusion proteins and peptide nucleic acids.

The CAG-3 cancer peptides, tumor antigen and their antigenic cancer epitopes may be purified and isolated from natural sources such as from primary clinical isolates, cell lines and the like. The CAG-3 cancer peptide and portions thereof are at least 90% pure, preferably at least 95% pure and as pure as 100%. The cancer peptides and their antigenic epitopes may also be obtained by chemical synthesis or by recombinant DNA techniques known in the arts. Techniques for chemical synthesis are described in J.M. Steward and J.D. Young, "Solid Phase Peptide Synthesis", W.H. Freeman & Co., San Francisco, 1969; M. Bodansky et al "Peptide Synthesis", John Wiley & Sons, Second Edition, 1976, and J. Meienhofer, "Hormonal Proteins and Peptides", Vol. 2, p. 46, Academic Press, New York, 1983 and E. Schroder and K. Kubke, "The Peptides", Vol. 1, Academic Press, New York, 1965.

The CAG-3 cancer peptides and their antigenic cancer epitopes may be formulated with pharmaceutically acceptable carriers into pharmaceutical

- 14 -

compositions by methods known in the art. The composition is useful as a vaccine to prevent or treat cancer. The composition may further comprise at least one immunostimulatory molecule. Immunostimulatory molecules to be used in conjunction with the cancer peptide or portion thereof for stimulating antigen specific

5 T cell responses include but are not limited to one or more major histocompatibility complex (MHC) molecules, such as class I and class II molecules, preferably a class I molecule. The composition may further comprise other stimulator molecules including B7.1, B7.2, ICAM-1, ICAM-2, LFA-1, LFA-3, CD72 and the like, and cytokines which include but are not limited to IL-1 through IL-15,  $\text{TNF}\alpha$ ,  $\text{IFN}\gamma$ ,

10 RANTES, G-CSF, M-CSF,  $\text{IFN}\alpha$ , CTAP III, ENA-78, GRO, I-309, PF-4, IP-10, LD-78, MGSA, MIP-1 $\alpha$ , MIP-1 $\beta$ , or combination thereof, and the like for immunopotentialation.

The stimulatory molecule may be provided as a physically separate entity or it may be provided in the membrane of an antigen presenting cell such as B-

15 cell, macrophage or dendritic cell, in the membrane of a liposome, or expressed on the surface of a transduced or transfected cell. DNA sequences of MHC immunostimulatory molecules are available from GenBank and the like.

The CAG-3 cancer peptides, tumor antigen and their antigenic cancer epitopes are useful in methods of preventing or treating cancer and useful in diagnostic

20 assay for detecting cancer or precancer in a mammal, including humans. The cancer peptides or portions thereof may be in the form of a derivative in which other constituents are attached thereto such as radiolabels, biotin, fluorescein. A targeting agent may also be attached to the tumor antigen, cancer peptides or portions thereof that allow for specific targeting to a specific organ, tumor or cell types. Such targeting

25 agents may be hormones, cytokines, cellular receptors and the like. The cancer peptide, tumor antigen and portions thereof may be prepared in the form of a kit, alone or in combination with other reagents.

Another aspect of the invention is a vaccine useful in inducing tumor-

- 15 -

specific cell-mediated immunity against cancer.

Approaches to cancer immunotherapy can be divided into active or passive categories. Active immunotherapy involves the direct immunization of cancer patients with cancer antigens in an attempt to boost immune responses against the tumor. Passive immunotherapy refers to the administration of immune reagents, such as immune cells or antibodies with antitumor reactivity with the goal of directly mediating antitumor responses.

Most prior attempts at active immunotherapy utilized either intact cancer cells or cancer cell extracts with the expectation that these materials contained tumor antigens in an amount and form capable of stimulating immune responses. The molecular identification of cancer antigens however, has open new possibilities for developing immunotherapies for the treatment of human cancer. A summary of some of these approaches is presented in Table 1.

- 16 -

Table 1 Cancer Therapies Based on the Molecular  
Identification of Cancer Antigens

- |    |  |
|----|--|
| 1. | Active immunotherapy with:   |
| 5  | <p>a. Immunodominant peptides</p> <p>1) alone</p> <p>2) combined with adjuvants</p> <p>3) linked to helper peptides, lipids or liposomes</p> <p>4) pulsed onto antigen presenting cells</p>  |
| 10 | <p>b. Immunodominant peptides with amino acids substitutions to increase binding to MHC molecules</p> <p>c. Proteins alone or combined with adjuvants</p>  |
| 15 | <p>d. "Naked" DNA encoding cancer antigens</p> <p>1) "gene gun" for intradermal injection</p> <p>2) intramuscular injection</p> <p>3) linked to lipids</p>   |
| 20 | <p>e. Recombinant viruses such as vaccinia, fowlpox or adenovirus encoding</p> <p>1) cancer antigens alone</p> <p>2) cancer antigens plus genes encoding cytokines, costimulatory molecules, or other genes to enhance the immune response</p> |
| 25 | <p>f. Recombinant bacteria such as BCG, Salmonella or Listeria encoding cancer antigens alone or in combination with immunostimulatory molecules</p>   |
| 2. | Active immunotherapy (above) followed by the administration of immunostimulatory cytokines.  |
|    | <p>1. IL-2</p> <p>2. IL-6</p>  |

- 17 -

3. IL-10
4. IL-12
5. IL-15, and the like.

3. Passive immunotherapy with anti-tumor lymphocytes raised by in vitro sensitization of TIL or PBL to
  1. immunodominant peptides pulsed onto antigen presenting cells (raise CD8 cells)
  2. antigenic proteins coincubated with antigen presenting cells (exogenous antigen presenting pathway to raise CD4 cells).

The insertion of the gene encoding CAG-3 cancer antigens into high efficiency expression systems such as E. coli, yeast or baculovirus and the like provides the opportunity to obtain large amounts of purified tumor antigen for use in immunization. Alternatively, the immunodominant peptides from these tumor antigens could readily be synthesized in vitro and purified in large amounts for immunization alone or in a form intended to improve their immunogenicity such as in combination with adjuvant, linkage to lipids/liposomes or helper peptides, or pulsed onto antigen presenting cells. Modification of individual amino acids of the immunodominant peptides to improve binding efficiency to MHC antigens can potentially increase immunogenicity compared to the native peptide.

Recent techniques utilizing "naked" DNA injected directly into muscle or into the skin have been shown to raise both cellular and humoral immune reactions to encoded antigens (Cooney, E.L., A.C. Collier, P.D. Greenberg, R.W. Coombs, J. Zarling, D.E. Arditti, M.C. Hoffman, S.L. Hu and L. Correy, 1991, *Lancet* 337:567; Wolff, J.A., R.W. Malone, P. Williams, W. Chong, G. Acsadi, A. Jani, and P.L. Felgner, 1990, *Science* 247:1465; Davis, H.L., R.G. Whalen, and B.A. Demeniex, 1993, *Hum. Gene Ther.* 4:151; Yang, N.S., J. Burkholder, B. Roberts, B. Martinelli, and D. McCabe, 1990, *Proc. Natl. Acad. Sci. USA* 87:9568; Williams, R.S., S.A. Johnston, M. Riedy, M.J. DeVit, S.G. McElligott, and J.C. Sanford, 1991, *Proc. Natl.*

- 18 -

*Acad. Sci. USA* 88:2726; Fynan, E.R., Webster, D.H. Fuller, J.R. Haynes, J.C. Santoro, and H.L. Robinson, 1995, *Proc. Natl. Acad. Sci. USA* 90:11478; Eisenbraun, M.D., D.H. Fuller, and J.R. Haynes, 1993, *DNA and Cell Bio.* 12:791; Fuller, D.H. and J.R. Haynes, 1994, *AIDS Res. Hum. Retrovir.* 10(11):1433; Acsadi, G., G. Dickson, D.R. Love, A. Jani, F.S. Walsh, A. Gurusinge, J.A. Wolff, and K.E. Davies, 1991, *Nature* 352:815). Techniques using nonviable DNA vectors have the advantage of ease of preparation and safety of administration. The nucleic acid sequence of the present invention is useful as an immunogen and as a DNA vaccine against cancer. The nucleic acid sequence of the present invention of CAG-3 or epitopes thereof may be administered using a gene gun in amounts to elicit a cellular response against a cancer cell. Nomogram quantities are useful for such purposes.

An effective form of immunization involves the incorporation of genes encoding immunogenic molecules into recombinant bacteria such as BCG, *Salmonella* or *Listeria* or into recombinant viruses such as vaccinia, fowlpox or adenovirus and the like. The genes encoding CAG-3 cancer antigens can be expressed either alone or in combination with genes encoding immunostimulatory molecules or other genes which can enhance the immune response following infection. Studies with model tumor antigens in murine models have shown that incorporation of the gene for interleukin-2 (IL-2) or B7.1 can increase the immunogenicity of model tumor antigens and even mediate the regression of established lung metastases bearing these antigens and even mediate the regression of established lung metastases bearing these antigens. Active immunotherapy followed by the exogenous administration of immunostimulatory cytokines such as IL-2, IL-6, IL-10, IL-12, or IL-15 may also be used to improve immune responses.

Passive immunotherapy with genetically modified immune cells (commonly referred to as adoptive immunotherapy) capable of recognizing human tumor antigens is effective in mediating the regression of cancer in selected patients with metastatic melanoma. In vitro techniques have been developed in which human

- 19 -

lymphocytes are sensitized in vitro to tumor antigen immunodominant peptides presented on antigen presenting cells. By repetitive in vitro stimulation cells can be derived with a far greater capacity to recognize human tumor antigens than the TIL that were used to clone the genes encoding these antigens. Thus by repeated in vitro sensitization with the cancer peptides, lymphocytes could be derived with 50 to 100 times more potency of TIL. The adoptive transfer of these cells may be more effective in mediating tumor regression in vivo than are conventionally grown TIL.

In the methods of preventing or inhibiting cancer, the cancer peptides or portions thereof may be administered via one of several routes including but not limited to intravenous, intramuscular, subcutaneous, intradermal, intraperitoneal, intrathecal, intrapleural, intrauterine, rectal, vaginal, topical, intratumor and the like.

Administration may be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration bile salts and fusidic acid derivatives. In addition, detergents may be used to facilitate permeation. Transmucosal administration may be by nasal sprays, for example, or suppositories. For oral administration, the cancer peptide, tumor antigen, portion or variant thereof is formulated into conventional oral administration form such as capsules, tablets and toxics.

In general, it is desirable to provide the recipient with a dosage of CAG-3 cancer peptide or portion thereof of at least about 1pg per Kg bodyweight, preferably at least about 1ng per Kg bodyweight, more preferably at least about 1 $\mu$ g or greater per Kg bodyweight of the recipient. A range of from about 1ng per Kg bodyweight to about 100mg per Kg bodyweight is preferred although a lower or higher dose may be administered. The dose is effective to prime, stimulate and/or cause the clonal expansion of CAG-3 cancer antigen specific T lymphocytes, preferably cytotoxic T lymphocytes, which in turn are capable of preventing or



- 20 -

inhibiting cancer in the recipient.

The dose is administered at least once and may be provided as a bolus or a continuous administration. Multiple administrations of the dose over a period of several weeks to months may be preferable. Subsequent doses may be administered as indicated.

In a method of treatment, a vaccine comprising the CAG-3 cancer peptide or portion thereof is administered to a mammal in an amount effective to prevent cancer in the mammals. Of particular interest is a vaccine comprising SEQ. ID NO: 25, 38, 46, 47 or combination thereof.

In a method of reducing tumor burden in animals having tumors the method comprises administration of an effective amount of a CAG-3 antigenic cancer epitope at a site of tumor burden, said amount is effective to reduce the size of the tumor at the site.

In another method of treatment, autologous cytotoxic lymphocytes or tumor infiltrating lymphocytes may be obtained from a patient with cancer. The lymphocytes are grown in culture and cancer antigen specific lymphocytes expanded by culturing in the presence of specific cancer peptides or antigenic cancer epitopes alone or in combination with at least one immunostimulatory molecule with cytokines. The antigen specific lymphocytes are then infused back into the patient in an amount effective to reduce or eliminate the tumors in the patient.

After immunization the efficacy of the vaccine can be assessed by production of immune cells that recognize the CAG-3 cancer antigen, as assessed by specific lytic activity, specific cytokine production, tumor regression or combination of these. If the mammal to be immunized is already afflicted with cancer or metastasis cancer the vaccine can be administered in conjunction with other therapeutic treatments such as immunomodulators, for example, IL-2, IL-6, IL-10, IL-12, IL-15, interferon, tumor necrosis factor and the like, chemotherapeutic drugs such as cisplatinum, antiviral such as gancyclovir, amphotericin B, antibiotics and the like.

- 21 -

Another aspect of the invention is a DNA sequence of a CAG-3 gene or portion thereof encoding a CAG-3 protein or epitope thereof.

In one embodiment, the DNA sequence comprises SEQ. ID NO.: 1, 2 or 3 portions thereof and functionally equivalent sequence variant thereof that encode a CAG-3 cancer peptide or portions thereof recognized by CAG-3 cancer antigen specific T lymphocytes including tumor infiltrating lymphocytes. Also encompassed by the present invention are nucleic acid sequences complementary, as well as anticomplementary to SEQ. ID NO: 1, 2 or 3.

In another embodiment, the DNA sequence comprises:  
CCT CGG GGC CGG GAG GAG GCG CCC CGC GGG (SEQ. ID NO: 51) which encodes SEQ. ID NO: 25.

In another embodiment, gene fragments encoding SEQ. ID NO: 14, 25, 34-38, 41, 42 and functionally equivalent sequence variants thereof are part of the present invention.

Another embodiment of the invention is an alternative open reading frame DNA sequence within SEQ. ID NO: 1 which encodes CAG 3 peptide or epitope thereof. In one embodiment the alternative open reading frame DNA sequence is SEQ. ID NO: 3 as depicted in Figure 3A which encodes the CAG3 protein, ORF2 - SEQ. ID NO: 5, or portion thereof.

In another embodiment, the DNA sequence of the present invention encodes the cancer peptide LAAQERRVPR of SEQ. ID NO: 47, the cancer peptide, AAQERRVPR of SEQ. ID NO: 46, cancer epitopes, fragments, derivatives or homologs thereof.

In one embodiment, the DNA sequence comprises:  
CTG GCG GCC CAG GAG AGG CGG GTG CCA CGG (SEQ. ID NO: 52) and variants thereof.

In another embodiment, the DNA sequence comprises:  
GCG GCC CAG GAG AGG CGG GTG CCA CGG (SEQ. ID NO: 53)

- 22 -

Due to degeneracy in the generic code, variations in the DNA sequence will result in translation of an equivalent cancer peptide. As a result, substitutions are included in the ambit of the invention as long as the substitution results in expression of a cancer peptide that is recognized by CAG-3 cancer antigen HLA-restricted T cells.

- 5 All or part of an open reading frame DNA sequence from the CAG-3 gene may be used as probes to identify and isolate the homologs of the cancer peptide in other mammalian species. In one embodiment, a human cDNA sequence is used to screen a mammalian cDNA library for a murine homolog nucleic acid sequence. Positive clones are selected and sequenced. Examples of tissue sources from which
- 10 the cDNA library can be synthesized include but are not limited to dermis, epidermis, solid tumors, melanomas, melanocytes, and the like. One skilled in the art will understand the appropriate hybridization conditions to be used to detect the homologs. Conventional methods for nucleic acid hybridization construction of libraries and cloning techniques are described in Sambrook et al, (eds) (1989) in "Molecular
- 15 Cloning. A Laboratory Manual" Cold Spring Harbor Press, Plainview, New York and Ausubel et al (eds) in "Current Protocols in Molecular Biology" (1987), John Wiley and Sons, New York, New York.

- Another aspect of the invention are nucleic acid probes for the detection and quantification of RNA that transcribes the CAG-3 cancer peptides or portion
- 20 thereof in biologic samples isolated from a mammal with cancer. Alterations in the level of RNA relative to a control RNA sample is useful in diagnosis and prognosis of the disease in the mammal.

- In one embodiment, mRNA is derived from tissue of a patient suspected of having cancer or precancer and compared with mRNA derived from a
- 25 healthy control subject. A quantitative and/or qualitative increase of the mRNA encoding a CAG-3 cancer peptide in the patient, as compared to the control, is indicative of cancer or precancer in the patient. The mRNA may be detected using oligonucleotide probes hybridizable with the mRNA. In one embodiment the probe is

- 23 -

hybridizable with the transcription product of SEQ. ID NO: 51.

Combinations of oligonucleotides pairs based on the sequence encoding the CAG-3 cancer peptide or portions thereof may be used as PCR primers to detect mRNA in biological samples using the reverse transcriptase polymerase chain reaction

(RT-PCR) process for amplifying selected RNA sequences. The present invention also encompasses in situ PCR and in situ RT-PCR for detection of DNA and RNA encoding the CAG-3 cancer peptides or portions thereof. The technique is preferred when the copy number of a target nucleic acid is very low, or when different forms of nucleic acids must be distinguished. The method is especially useful in detecting and differentiating precancer and cancer cells from normal cells.

The present invention also encompasses antisense oligonucleotides which bind to certain complementary ('sense') regions on mRNA resulting in inhibition of synthesis of CAG-3. Such antisense oligonucleotides are single stranded nucleic acid of about 12 to about 25 mononucleotides. Such antisense oligonucleotides may be made by methods known in the art as described by Uhlmann, E. et al. Antisense oligonucleotides, structure and function of In: Molecular Biology and Biotechnology Ed. R.A. Meyers, VCH Publishers, Inc., New York, NY, 1995, pp. 38-44.

The present invention also encompasses a vector comprising the DNA sequence encoding CAG-3 cancer peptides or the antigenic cancer epitope. Optionally the vector may also comprise a DNA sequence encoding at least one immunostimulatory molecule. The vector may also contain a gene encoding green fluorescent protein for use in detecting localization of CAG-3 in cells and tissues.

Eukaryotic expression vectors include but are not limited to retroviral vectors, vaccinia virus vectors, adenovirus vectors, herpes virus vectors, fowlpox virus vectors, baculovirus vectors, human papillomavirus vectors, equine encephalitis vectors, influenza virus vectors and the like.

The present invention encompasses novel recombinant virus expressing

- 24 -

a CAG-3 cancer peptide or portion thereof encoded by an open reading frame nucleic acid sequence of a gene, fragments or variants thereof. The recombinant virus may also express at least one immunostimulatory molecule. The recombinant virus is capable of eliciting or upregulating a cell-mediate immune response in a mammal for the purpose of preventing or treating cancer in the mammal, particularly humans.

A host cell infected with the recombinant virus expresses the cancer peptide, portion thereof, or antigenic cancer epitope, alone or in combination with at least one immunostimulatory molecule. The host cell may also be infected with a recombinant virus expressing an HLA class I molecule.

Methods for constructing and expressing exogenous gene products from recombinant vaccinia virus vectors are disclosed by Perkus et al Science 229:981-984, 1985, Kaufman et al Int. J. Cancer 48:900-907, 1991, Moss Science 252:1662, 1991, Smith and Moss BioTechniques Nov/Dec, p. 306-312, 1984, and U.S. Patent No. 4,738,846. Sutter and Moss (Proc. Nat'l Acad. Sci. U.S.A. 89:10847-10851, 1992) and Sutter et al (Virology 1994) disclose the construction and use as a vector, the non-replicating recombinant Ankara virus (MVA, modified vaccinia Ankara) which may be used as a viral vector in the present invention. Baxby and Paoletti (Vaccine 10:8-9, 1992) disclose the construction and use as a vector, a non-replicating poxvirus, including canarypox virus, fowlpox virus and other avian species for use as a viral vector in the present invention.

The vectors of the present invention may be placed in an appropriate host cell for the expression of the CAG-3 cancer peptide or antigenic cancer epitope. Eukaryotic host cell lines include, but are not limited to COS cells, CHO cells, Hela cells, NIH/3T3 cells, insect cells, antigen presenting cells such as dendritic cells and the like. Optionally the host cell may also express a stimulatory molecule. In the case where the host cells express both the cancer peptide or antigenic cancer epitope in combination with at least one MHC (or HLA) molecule, it is preferable that a eukaryotic expression system be used to allow for proper glycosylation. The

- 25 -

expression of both the cancer antigen and the immunostimulatory molecule by the host cell provides the necessary MHC restricted peptide to specific T cells and the appropriate signal to the T cell to aid in antigen recognition and proliferation or clonal expansion of antigen specific T cells. The overall result is an upregulation of the immune system. The upregulation of the immune response is manifest by an increase in cancer antigen specific cytotoxic lymphocytes which are able to kill or inhibit the growth of cancer or precancer cells.

The DNA may be inserted into the host cell by transfection, transduction, liposomes and the like by methods known in the art. (Sambrook et al, 1989, in: "Molecular Cloning A Laboratory Manual", Cold Spring Harbor press, Plainview, New York). For liposomes, cationic lipids are preferred, for example, polycationic lipid, dimyristyloxypyl-3-dimethyl-hydroxyethyl ammonium (DMRIE) complexed with the neutral phospholipid dioleoyl phosphatidyl-ethanolamine (DOPE) as disclosed by Nabel, E.G. et al, 1992, Hum. Gene. Ther. 3:367-275; Nabel, G.J. et al, 1992, Hum. Gene Ther. 3:649-656; Stewart, M.J. et al 1992 Hum. Gene Ther. 3:399-410; Nabel, G.J. et al 1993 Proc. Natl. Acad. Sci. USA 90:11307-11311; and Harrison, G.S. et al 1995 Bio Techniques 19:816-823.

The recombinant CAG-3 cancer protein, tumor antigen or antigenic cancer epitope expressed by the host cells may be purified from cell lysates or cell supernatants by standard protein purification procedures known in the art. These include but are not limited to molecular sieve chromatography, ion-exchange chromatography, isoelectric focusing, gel electrophoresis, affinity chromatography, HPLC, reverse phase HPLC and the like. (Ausubel et al, 1987, in Current Protocols in Molecular Biology, John Wiley and Sons, New York, NY). Immunoaffinity chromatography may also be used for purification using anti-cancer protein antibodies or antigen binding fragments thereof as described herein, as the immunoaffinity agent.

The recombinant virus may also be used as a therapeutic or vaccine. In such uses it is desirable to provide the recipient with a dosage of recombinant virus in

- 26 -

the range of from about  $10^5$  to about  $10^{10}$  plaque forming units/mg mammal, although a lower or higher dose may be administered.

The recombinant viral vector may be introduced into a mammal either prior to any evidence of cancer such as melanoma or to mediate regression of the disease in a mammal afflicted with a cancer such as melanoma. Examples of methods for administering the viral vector into mammals include, but are not limited to, exposure of cells to the recombinant virus *ex vivo*, or injection of the recombinant virus into the affected tissue or intravenous, subcutaneous, intradermal, intramuscular and the like administration of the virus. Alternatively, the recombinant viral vector or combination of recombinant viral vectors may be administered locally by direct injection into the cancerous lesion or topical application in a suitable pharmaceutically acceptable carrier. The quantity of recombinant viral vector, carrying the nucleic acid sequence of interest is based on the titer of virus particles. A preferred range for immunization is about  $10^5$  to  $10^{10}$  virus particles per mammal, preferably a human.

The invention provides a transgenic animal which has incorporated into its genome one or more copies of the DNA sequence encoding a CAG-3 cancer peptide or portion thereof. The general method of producing transgenic animals is described in Krimpenfort et al U.S. Patent No. 5,175,384, Leder et al U.S. Patent No. 5,175,383, Wagner et al U.S. Patent No. 5,175,385, Evans et al U.S. Patent No. 4,870,009 and Berns U.S. Patent No. 5,174,986. The incorporation of the gene results in overexpression, altered expression or expression of multiple forms or variants of the CAG-3 cancer peptides. The resulting transgenic animal are useful in studies of the development of cancer or tumor antigen of the present invention. The animal model is useful in screening vaccines and chemotherapeutic drugs for cancer treatment. The transgenic animal is also useful in studies of the development of cancer.

This invention further comprises an antibody or antigen binding portion thereof elicited by immunization of the CAG-3 cancer peptide or antigenic cancer epitope of the present invention. In the case where the cancer peptide or antigenic

- 27 -

cancer epitope is comprised of only a few amino acids, the cancer peptide or antigenic cancer epitope may be conjugated to a carrier protein in order to elicit an antibody response. Carrier proteins such as KLH, tetanus toxoid and the like and methods of conjugation are known in the art. The antibody has specificity for and reacts or binds with the CAG-3 cancer peptide and the antigenic cancer epitope of the present invention.

Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules or these portions of an immunoglobulin molecule that contain the antigen binding site, including those portions of immunoglobulin molecules known in the art as F (ab), F (ab')<sub>2</sub>, humanized chimeric antibody, and F (v). Polyclonal or monoclonal antibodies may be produced by methods known in the art. (Kohler and Milstein (1975) Nature 256, 495-497; Campbell "Monoclonal Antibody Technology, the Production and Characterization of Rodent and Human Hybridomas" in Burdon et al (eds.) (1985) "Laboratory Techniques in Biochemistry and Molecular Biology", Vol. 13, Elsevier Science Publishers, Amsterdam). The antibodies or antigen binding fragments may also be produced by genetic engineering. The technology for expression of both heavy and light chain genes is the subject of the PCT patent applications: publication number WO 901443, WO 9014424, Huse et al (1989) Science 246:1275-1281, and U.S. Patent No. 4,946,778. Humanized immunoglobulins having one or more complementary determining regions and methods of making the antibodies are disclosed in U.S. Patent No. 5,585,089 and 5,530,101.

In one embodiment, the antibodies of the invention are used in immunoassays to detect CAG-3 cancer peptides or portions thereof in biological samples. The antibodies or antigen binding fragments thereof may be used to detect cancer peptides in tissue biopsy samples from a mammal afflicted with cancer. Assessment of the cancer antigen in a diseased tissue can be used to prognose the progression of the disease in a mammal or may diagnose the efficacy of a treatment.



- 28 -

The immunoassay may be a radioimmunoassay, Western blot assay, immunofluorescent assay, enzyme immunoassay, chemiluminescent assay, immunohistochemical assay and the like and may be performed in vitro, in vivo or in situ. Standard techniques known in the art for ELISA are described in "Methods in Immunodiagnosis", 2nd Edition, Rose and Bigazzi, eds. John Wiley & Sons, 1980; Campbell et al "Methods and Immunology", W.A. Benjamin, Inc., 1964; and Oellerich, M. 1984, J. Clin. Chem. Clin. Biochem. 22:895-904. Conventional methods for immunohistochemistry are described in Harlow and Lane (eds) (1988) In "Antibodies A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor, New York; Ausbel et al (eds) (1987) In Current Protocols In Molecular Biology, John Wiley and Sons (New York, NY). Biological samples appropriate for such detection assays include but are not limited to cells, tissue biopsy, whole blood, plasma, serum, sputum, cerebrospinal fluid, pleural fluid, urine and the like.

The antibodies or antigen binding fragments of the present invention may also be used in immunotherapy. The antibodies or antigen binding fragment thereof is provided to a mammal in an amount sufficient to prevent, lessen or attenuate the severity, extent or duration of the cancer.

All articles and patents referred to are incorporated herein by reference.

While the invention is described above in relation to certain specific embodiments, it will be understood that many variations are possible, and that alternative materials and reagents can be used without departing from the invention. In some cases such variations and substitutions may require some experimentation, but will only involve routine testing.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention and others can, by applying current knowledge, readily modify and/or adopt for various applications such specific embodiments without departing from the generic concept, and therefore such adaptations and modifications are intended to be comprehended within the meaning

and range of equivalents of the disclosed embodiments.

### Example 1

#### Materials and Methods

##### *Chemicals and Reagents*

- 5           The following chemicals and reagents were purchased from the sources indicated: RPMI 1640, AIM-V media, Lipofectamine, G418 (GIBCO BRL, Gaithersburg, MD); the eukaryotic expression vector pCR3 (Invitrogen, San Diego, CA); anti-HLA-A31 monoclonal antibody (One lambda, Canoga Park, CA); anti-immunoglobulin M antibody conjugated with fluorescein isothiocyanate (Vector  
10   Laboratories, Inc., Burlingame, CA).

##### *Cytotoxic T lymphocytes (CTLs) and cell lines*

- TIL 586 were isolated from the tumor specimen of a patient with metastatic melanoma and grown in medium containing IL-2 (6000 IU/ml) (Chiron) for 32-60 days as previously described (Topalian, S., D. Solomon, F. P. Avis, A. E.  
15   Chang, D. L. Freeksen, W. M. Linehan, M. T. Lotze, C. N. Robertson, C. A. Seipp, P. Simon, C. G. Simpson, and S. A. Rosenberg, 1988, *J. Clin. Oncol.* 6:839-53). TIL586 and TIL1244 were predominantly CD8<sup>+</sup> T cells. TIL1200 were grown under the same conditions as described for TIL586. TIL1244 recognized the TRP-2 peptide in the context of HLA-A31 and -A33 (31). The T cell clones or cloids were generated by  
20   limiting dilution methods (at 1 cell/well) from the TIL586 cell line, using allogeneic PBL (1 x 10<sup>3</sup> cells/well) as feeder cells in RPMI1640 containing 10% human AB sera and 500 IU IL-2. After 12 days, the T cell clones were expanded in AIM-V medium containing 6000 IU/ml IL-2. To obtain an optimal expansion, we used the OKT3 expansion method, described by S. Riddell (32). Briefly, on day 0, 5 x 10<sup>4</sup> to 5 x 10<sup>5</sup> T  
25   cells were cocultured with HLA-A31<sup>+</sup> PBL (500:1, PBL:T cell ratio) and 586EBV B cells (100:1, EBV:T cell ratio) in 25 ml of RPMI 1640 containing 11% human sera, 30 ng/ml OKT3 Ab, and antibiotics. On day 1, IL-2 was added at a final concentration of 180 IU/ml. The medium was changed with fresh medium containing 11% human sera

- 30 -

and 180 IU/ml IL-2 on day 5. The medium was then changed every 3 days. On days 12 through 14, T cells were harvested, counted and cryopreserved.

Melanoma cell lines 397mel, 397mel/A31, 586mel, 624mel, 624mel/A31 and EBV transformed B-cell lines 586EBV and 1510EBV were established in this laboratory and cultured in RPMI 1640 medium containing 10% fetal calf serum (FCS). Normal cultured melanocytes derived from infant foreskin (NHEM680 purchased from Clonetics, CA) were cultured in melanocyte growth medium (MGM; Clonetics, CA). The COS-7 cell line was provided by Dr. W. Leonard (NIH).

295Br and 1315Br, fresh cryopreserved breast tumor digests, were cleaned with Ficoll gradient before use in T cell assays; 1295 fibroblast were cultured cells from the autologous patient for 22 to 64 days. 1315Br, culture A, were breast tumor cells grown in immunodeficient mice and then cultured in keratinocyte-SFM/2% FCS medium (Life Technologies), and 1315 Br, culture B, were grown in Hams F12/5% FCS for 77 to 80 passages; these cells were kindly provided by Dr. Stephen Ethier, University of Michigan, Ann Arbor, MI. 1398Br was an human papillomavirus (HPV) E6/E7-immortalized breast tumor line established in the Surgery Branch, National Cancer Institute. Prostate tumor lines 1535Pro, 1542Pro, and 1510 fibroblast were HPV E6/E7-immortalized cell lines.

#### ***cDNA library construction***

Total RNA was extracted from 586mel using Trizol reagent (Life Technologies). Poly(A) RNA was purified from total RNA by the poly AT tract system (Promega, Madison, WI) and then converted to cDNA using a cDNA construction kit (Life Technologies) with an oligo(dT) primer containing a *NotI* site. The cDNA was ligated to *BstXI* adaptors and digested with *NorI*, then ligated to the expression vector pcDNA3.1. The cDNA library was electroporated into DH10B cells (Life Technologies). Plasmid DNA pools, each consisting of ~ 100 cDNA clones, were prepared from bacteria.

- 31 -

***cDNA Library Screening and GM-CSF Secretion Assay***

DNA transfection and GM-CSF assay were done as previously described (Wang, R. F., P. F. Robbins, Y. Kawakami, X. Q. Kang, and S. A. Rosenberg, 1995, *J. Exp. Med.* 181:799-804). Briefly, 200 µg of DNA carrying a  
5 different fragment and 50 ng of the HLA-A31 DNA were mixed with 2 µl of lipofectamine in 100 µl of serum-free DMEM for 15-45 min. The DNA/lipofectamine mixture was then added to the COS-7 ( $5 \times 10^4$ ) cells and incubated overnight. The following day, cells were washed twice with DMEM medium. TIL586, CTL clone 5 or CTL clone 10 were added at a concentration of  $5 \times 10^4$  cells/well in AIM-V  
10 medium containing 120 IU/ml of IL-2. After 18-24 h incubation, 100 µl of supernatant was collected and GM-CSF was measured in a standard ELISA assay (R + D Systems, Minneapolis, MN). For peptides, 586EBV, 1510EBV and T2 cells were incubated with peptides at 37°C for 90 min, and then washed three times with AIM-V medium containing 120 IU/ml of IL-2. T cells were added and incubated for  
15 additional 18-24 h, 100 µl of supernatant was collected for GM-CSF assay. In some experiments, IFN-γ release assays were done using a standard ELISA kit (Endogen, Woburn, MA).

***Northern Blot Analysis***

Total RNA was isolated by the guanidine isothiocyanate/cesium  
20 chloride centrifugation method. Total RNA from normal human tissue was purchased from Clontech (Palo Alto, CA). Twenty micrograms of total RNA was subjected to electrophoresis in a 1.2% formaldehyde agarose gel and transferred to a nylon membrane. An 0.8-kb DNA fragment of the *NY-ESO-1* gene was labeled with [ $\alpha$ -<sup>32</sup>P]CTP by the random priming method. Prehybridization and hybridization were  
25 performed according to the QuickHyb protocol (Stratagene, La Jolla, CA). Membranes were washed twice with  $2 \times \text{SSC}/0.1\% \text{ SCD}$  at room temperature for 15 and twice with  $0.1 \times \text{SSC}/0.1\% \text{ SDS}$  at 60° for 30 min. The autoradiography was performed at -70°C.

- 32 -

**Reverse Transcriptase-PCR**

Total RNA was extracted from tumor cell lines as described above. Five hundred nanograms of total RNA was used for conversion of RNA to cDNA by avian myeloblastosis virus (AMV) reverse transcriptase. cDNA was then amplified by PCR using the ESO-P2 (5'GCGGCTTCAGGGCTGAATGGATG) and ESO-P5 (5'-AAGCCGTCCTCCTCCAGCGACA) primers and One-Step RT-PCT system (Life Technologies). PCR products were amplified under denaturation conditions at 94°C for 30 s, annealing at 55° for 30 s, extension at 72° for 3 min for 40 cycles, and final elongation at 72° for 10 min. PCR products were analyzed on a 3% agarose gel.

**Cytotoxic lysis assays**

Cytolytic assay was done as previously described (Kawakami, Y et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:6458-62). Briefly, the target cells were labeled with chromium for 90 min. After washing three times, the cells were incubated with peptides at a concentration of 1 µg/ml for 90 min. The cells were washed again, counted, and then mixed with TIL586 or CTL clone 5 at the indicated ratio of effector : targets (E : T). Chromium release was measured after 4 h incubation. The peptides were synthesized by a solid-phase method using a peptide synthesizer (Model AMS 422, Gilson Co., Inc., Worthington, OH). Some peptides were purified by HPLC and had greater than 98% in purity. The mass of some peptides was confirmed by mass spectrometry analysis. For titration of the CAG-3 peptide recognized by TIL586, 586EBV B cells were incubated with various concentrations of the purified CAG-3 peptide or portion thereof. Percentage of specific lysis was determined from the equation  $(A-B)/(C-B) \times 100$  where A is lysis of 586EBV B cells by TIL586 or clone 5 in the presence of a peptide, B is spontaneous release from 586EBV B cells in presence of the same peptide but in the absence of effector cells, and C is the maximum chromium release. Cold target inhibition of cytotoxicity was performed using <sup>51</sup>Cr-labeled 586mel or 624mel cells as "hot" targets and 586EBV B and T2 cells pulsed with peptides as "cold" targets.

- 33 -

## Example 2

### In vivo Protection Assay

For in vivo protection studies, MHLA-A31<sup>+</sup> transgenic mice are immunized with 0, 1pg, 1ng, 1μg, 1mg or 100mg of cancer peptide (SEQ. ID NO: 4, 5, 14, 25, 34-38, 41, 42, 46 or 47), intravenously at day zero and day 14 before a subcutaneous challenge with 10<sup>4</sup> CAG-3 B16 mouse melanoma cells or intravenous challenge with 5 x 10<sup>4</sup> CAG-3 B16 mouse melanoma cells. Mice receiving tumor cells subcutaneously are observed twice a week for tumor development and the size determined. Mice receiving tumor cells intravenously are euthanized on day 12 and the number of lung metastases determined as described by Houghton, A.N. 1994 J. Exp. Med. 180:1-40.

## Example 3

### In vivo Treatment Assay

For in vivo treatment, MHL-A31<sup>+</sup> transgenic mice are challenged with either 1 x 10<sup>5</sup> or 5 x 10<sup>5</sup> CAG-3 B16 mouse melanoma cells intravenously in order to establish pulmonary metastases. Mice are subsequently vaccinated with a recombinant virus expressing cancer peptide (SEQ. ID NO: 4, 5, 14, 25, 34-38, 41, 42, 46 or 47) at 10<sup>5</sup> PFU/mg body weight. Mice are euthanized on day 12 and the number of pulmonary metastases in vaccinated mice vs. non-vaccinated mice determined.

## Example 4

### Cancer Antigen Specific T Lymphocytes

#### Immunotherapy

T-lymphocytes presensitized to a melanoma antigen may be effective in therapeutically treating mammals afflicted with a melanoma. T-lymphocytes are isolated from peripheral blood or melanoma tumor suspensions and cultured in vitro (Kawakami, Y. et al, 1988, J. Exp. Med. 168:2183-2191).

The T lymphocytes are exposed to the cancer peptide (SEQ. ID NO: 4, 5, 14, 25, 34-38, 41, 42, 46 or 47) at a concentration of 1 μg/ml alone or in the

- 34 -

presence of IL-2, resensitized and expanded in culture. T-lymphocytes exposed to the cancer peptide are administered to a mammal at about  $10^9$  to  $10^{12}$  lymphocytes per mammal. The lymphocytes are administered either intravenously, intraperitoneally or intrasessionally. The treatment may be administered concurrently with other

- 5 therapeutic treatments such as cytokines, surgical excision of melanoma lesions and chemotherapeutic drugs.

### **Example 5**

#### **Treatment of Patients with Metastatic Melanoma**

- 10 In this protocol, patients with advanced melanoma are immunized with an antigenic cancer epitope.

Patients eligible for the trial must have evidence of measurable or evaluable metastatic melanoma that has failed standard effective therapy. Patients must have tumors that express the CAG-3 antigen as evidenced by PCR or Northern Blot analysis of tumor cell RNA.

- 15 Patients receive either 1ng, 1 $\mu$ g, 1mg or 500mg/kg body weight of a cancer peptide (SEQ. ID NO: 4, 5, 14, 25, 34-38, 41, 42, 46 or 47) via intravenously at day zero, day 7 and day 14 alone or in combination with IL2 and/or an immunostimulatory molecule. Patients are evaluated for toxicity, immunologic effects and therapeutic efficacy.

- 20 Lymphocytes taken from the treated patients are tested for specific response to the CAG-3 cancer antigen (SEQ. ID NO: 4, 5, 14, 25, 34-38, 41, 42, 46 or 47).

- A complete response is defined as the disappearance of all clinical evidence of disease that lasts at least four weeks. A partial response is a 50% or  
25 greater decrease in the sum of the products of the perpendicular diameter of all measurable lesions for at least four weeks with no appearance of new lesions or increase in any lesions. Minor responses are defined as 25-49% decrease in the sum of the products of the perpendicular diameters of all measurable lesions with no

- 35 -

appearance of new lesions and no increase in any lesions. Any patient with less than a partial response is considered a non-responder. The appearance of new lesions or greater than 25% increase in the product of perpendicular diameters of prior lesions following a partial or complete response is considered as a relapse.

5

#### **Example 6**

##### **Recognition of CAG-3 antigens on tumor cells by CTL clones**

In previous studies, we have isolated a number of T cell clones from the TIL586 bulk cell line by the limiting dilution method (Wang et al. 1996b, J. Exp. Med. 183:1131-1140). Several clones recognized TRP-1 or TRP-2. However, two T cell clones isolated from the same TIL586 cell line recognized neither TRP-1 or TRP-2 but were capable of recognizing 586mel as well as HLA-A31+ melanocytes (Fig. 1A through 1C). These results suggested that these T cell clones recognized additional tumor antigens on the 586mel tumor cells. These T cell clones were then expanded and CTL clones 5 and 10 were used to screen cDNA libraries.

15

#### **Example 7**

##### **Identification of a cDNA encoding a tumor antigen recognized by T cell clones**

To determine the HLA molecule responsible for presenting antigen to CTL clone 5 and 10, we transfected HLA-A31 cDNA into A31-negative tumor lines 397mel and 624mel and tested for recognition by the CTL clone. Transfectants of 397mel and 624mel expressing HLA-A31 were significantly recognized by CTL clone 5 and 10 (Table 1).

20



- 36 -

**Table 1**  
**Specific secretion of GM-CSF by CTL clone 5 and 10 is HLA-A31-restricted**

Cell lines	Stimulators		GM-CSF secretion (pg/ml)	
	Transfected gene	HLA-A31 expression	clone 5	clone 10
None	None	-	<50	<50
397mel	None	-	<50	<50
397mel	HLA-A31	+	3840	4280
624mel	None	-	<50	<50
624mel	HLA-A31	+	4650	4320
586mel	None	+	4050	3900
586EBVB	None	+	<50	<50

GM-CSF in the supernatant was measured after 24 h incubation of  $5 \times 10^4$  CTL clone

5 or 10 cells with melanoma cell lines or media alone.

Since only a limited number of T cells were available, we first tested

whether or not these T cells recognized previously identified tumor antigens or melanocyte-lineage differentiation proteins. Recognition of COS-7 cells transfected with HLA-A31 cDNA and genes encoding the known tumor antigens or putative antigens including MART-1 (Kawakami et al. 1994a, Proc. Nat'l Acad. Sci USA 91:3515-3519), gp75 (Wang et al. 1995, J. Exp. Med. 181:799-804), gp100 (Kawakami et al. 1994b, Proc. Nat'l Acad. Sci. USA 91:6458-6462), tyrosinase (Brichard et al. 1993, J. Exp. Med. 178:489-495), and TRP-2 (Yokoyama et al. 1994, Biochim. Biophys. Acta 1217:317-321; Bouchard et al. 1994, Eur. J. Biochem. 219:127-134) by CTL clone 5 or 10 was tested. COS cells transfected with HLA-A31 alone, TRP-1 or TRP-2 alone did not confer recognition by the T cell clones (Figure 2). Moreover, COS cells transfected with HLA-A31 and other tumor genes failed to stimulate GM-CSF release from T cells, indicating that the T cell clone 5 or 10 did not recognize these tumor antigens, but recognized a new tumor antigen in the context of HLA-A31.

### Example 8

#### Cloning of CAG-3 Gene

To identify the new tumor Ag(s) recognized by CTL clones 5 and 10, we made a cDNA library derived from 586mel. Each cDNA pool consisted of ~100 cDNA clones. After screening a total of  $2.5 \times 10^5$  cDNA clones, we identified 15 positive cDNA pools that conferred T cell recognition by CTL 5 or 10 when cotransfected into COS-7 along with HLA-A31 cDNA. The positive clones were then tested for recognition by both CTL clones 5 and 10. It was found that both CTL clones recognized the same cDNA pools. Individual colonies were isolated from each positive pool and tested for T cell reactivity. Representative data are shown in Fig. 4. CTL clone 5 recognized COS-7 cotransfected with cDNA clone 1 or 2 and HLA-A31, but not COS-7 alone, COS-7 transfected with cDNA clone 1 or 2, or transfected only with the HLA-A31 cDNA (Fig. 4). DNA sequencing analysis indicated that all 10 cDNA positive clones from different positive pools overlapped, and the DNA and the

- 38 -

amino acid sequence of these clones is shown in Fig. 3A. A search of all available databases revealed that the coding region of this gene, we named cancer antigen gene 3 (CAG-3, Genbank Accession Number AF038567), was identical to NY-ESO-1 which was recently reported to be an Ag recognized by a serum Ab derived from a patient with esophageal cancer (29). Our longest cDNA clone contained an additional 37 nucleotides upstream of the previously reported 5'-end untranslated region. Two other proteins in the databases were found to contain homologous sequences in a limited region. The gene product of NY-ESO-1 (we have used NY-ESO-1 for CAG-3 in the following text) has 52% similarity to the tegument protein (UL36) of herpes simplex virus type 1 in the 64-amino acid segment and 47% similarity to enterobactin synthetase component F (serine-activating enzyme) in the 48-amino acid region (Fig. 3B).

#### Example 9

##### **Breast Cancer Cells Recognized by CTL Clones**

Northern blot analyses were performed using *NY-ESO-1* cDNA as a probe to evaluate the expression pattern in different tissues. Testis tissue was shown to be the only positive in the expression of NY-ESO-1 among the normal human tissues tested. NY-ESO-1 was found to be expressed in several types of cancers including melanoma and breast cancer (data not shown). These results were in consistent with data previously reported (29). To determine whether the melanoma reactive CTLs would also recognize other tumor cells, we tested T cell reactivity against HLA-A31 positive breast and prostate tumor cells by CTL clone 5. We used IFN- $\gamma$  to monitor T cell recognition in these experiments because prostate tumor cells alone secrete GM-CSF, but not IFN- $\gamma$ . As shown in Table 2, CTL clone 5 was capable of recognizing HLA-A31 positive 1295Br and 1315Br fresh breast tumor cells, but neither HLA-A31 negative 1405Br and 1411Br fresh breast tumor cells, nor HLA-A31 positive 1295 fibroblast cells derived from the autologous patient 1295. In addition, CTL clone 5

- 39 -

recognized the cultured HLA-A31 positive 1315Br (culture A and B) cells (Table 2), but did not respond to the cultured HLA-A31 negative cultured 1386Br breast cancer cells, nor the cultured HLA-A31 positive 1510 fibroblast. Although CTL clone 5 somehow did not respond to the cultured HLA-A31 positive 1315Br (culture A and B) cells in experiment 1, additional experiments showed T cell recognition of the cultured HLA-A31 positive 1315 Br (culture A and B) cells (data not shown). The expression of HLA-A31 and NY-ESO-1 in the fresh 1315Br and 1295Br tumor cells was confirmed by FACS analysis and RT-PCR analysis (data now shown). Expression of NY-ESO-1 was detected by RT-PCR using primers ESO-P2 and ESO-P5 in both 1295 and 1315 fresh breast tumor cells. CTL clone 5 recognized neither the HLA-A31<sup>+</sup> 1535 prostate tumor cells because of lack of expression of NY-ESO-1 nor the HLA-A31-1542 prostate tumor cells (Table 2). These results strongly suggested that an antigenic peptide of NY-ESO-1 was expressed at sufficient levels on the surface of breast tumor cells to be recognized by T cells. Therefore, NY-ESO-1 may serve as an immune target for the immunotherapy of patients with breast cancer. NY-ESO-1 is also expressed in a high percentage (about 67%) of small cell lung carcinoma (data not shown).

- 40 -

**Table 2**  
**Recognition of breast tumor cells by CTL clone 5<sup>a</sup>**

Stimulators		IFN $\gamma$ release (pg/ml) by CTL clone 5	
Target cells	HLA-A31 expression	Expt. 1	Expt. 2
586mel	+	225	488
397mel	-	7	35
1315Br (fresh tumor #1)	+	171	520
1315Br (fresh tumor #2)	+	106	126
1295Br (fresh tumor)	+	265	358
1295 Fibroblast	+	4	24
1405 Br (fresh tumor)	-	15	28
1411Br (fresh tumor)	-	ND	74
1315Br (culture A)	+	23	224
1315Br (culture B)	+	0	155
1398Br	-	0	36
1510 Fibroblast	+	8	ND
1535 Prostate	+	24	ND
1542 Prostate	-	17	ND

<sup>a</sup>IFN- $\gamma$  in the supernatant was measured after an 18-h incubation of  $1 \times 10^5$  CTL clone

- 5 5. In experiments 1 and 2 cytokine release from stimulators alone was <10 pg/ml.

00529200-061300

- 41 -

Example 10**The peptide epitopes recognized by CTL clone 5**

To screen for epitopes from the coding region of CAG-3 DNA an HLA peptide motif search was performed. These results are shown in Table 4 and Table 5.

00526205-051300

**Table 4**  
**HLA peptide motif search results**

<b>User Parameters and Scoring Information</b>	
Method selected to limit number of results	explicit number
Number of results requested	30
HLA molecule type selected	A-3101
Length selected for subsequences to be scored	10
Echoing mode selected for input sequence	Y
Echoing format	numbered lines
Length of user's input peptide sequence	180
Number subsequence scores calculated	171
Number of top-scoring subsequences reported back in scoring output table	30

<b>Scoring Results</b>			
Rank	Start Position	Subsequence Residue Listing	Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence)
1	127	TVSGnILTIR	4.000 Seq. ID No. 84
2	134	TIRLrAADHR	2.000 Seq. ID No. 85
3	97	ATPMaELAR	2.000
4	170	FLAQpPSGQR	2.000
5	98	TPMEaELARR	1.200
6	77	RCGArGPESR	0.600
7	68	AASG1NGCCR	0.200
8	171	LAQPpSGQRR	0.200
9	163	TQCF1PVFLA	0.120 Seq. ID No. 86
10	153	LQQLsLLMWI	0.080 Seq. ID No. 87
11	115	PLPVpGVLLK	0.080 Seq. ID No. 88
12	152	CLQQ1SLLMW	0.080 Seq. ID No. 89
13	131	NILrILTAA	0.080 Seq. ID No. 90
14	126	FTVSgNILTI	0.080 Seq. ID No. 91
15	43	RGPrgAGAAR	0.060
16	158	LLMWiTQCFL	0.060 Seq. ID No. 92
17	87	LLEFyLAMPF	0.040 Seq. ID No. 93
18	161	WITQcFLPVF	0.040 Seq. ID No. 94
19	157	SLLmwITQCF	0.040 Seq. ID No. 95
20	93	AMPFaTPMEA	0.040 Seq. ID No. 96
21	72	LNGCcRCGAR	0.040
22	154	QQLS1LMWIT	0.040 Seq. ID No. 97
23	86	RLLEfYLAMP	0.024 Seq. ID No. 98
24	143	RQLQ1SISSC	0.024 Seq. ID No. 99
25	71	GLNGcCRCGA	0.020 Seq. ID No. 100
26	91	YLAMPfATPM	0.020 Seq. ID No. 101
27	22	GIPDgPGGNA	0.020 Seq. ID No. 102
28	53	ASGPgGGAPR	0.020
29	144	QLQLsISSCL	0.020 Seq. ID No. 103
30	133	LTIR1TAADH	0.020 Seq. ID No. 104

**Table 5**  
**HLA peptide motif search results**

<b>User Parameters and Scoring Information</b>	
Method selected to limit number of results	explicit number
Number of results requested	30
HLA molecule type selected	A-3101
Length selected for subsequences to be scored	9
Echoing mode selected for input sequence	Y
Echoing format	numbered lines
Length of user's input peptide sequence	181
Number subsequence scores calculated	173
Number of top-scoring subsequences reported back in scoring output table	30

<b>Scoring Results</b>			
Rank	Start Position	Subsequence Residue Listing	Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence)
1	172	AQPPSGQRR	2.000
2	98	TPMEAEAR	1.200
3	99	PMEAEAR	0.400
4	86	RLLEFYLAM	0.240 Seq. ID No. 63
5	38	GATGGRGPR	0.200
6	44	GPRGAGAAAR	0.200
7	171	LAQPPSGQR	0.200
8	154	QQLSLLMWI	0.160 Seq. ID No. 64
9	116	LPVPGVLLK	0.160 Seq. ID No. 65
10	120	GVLLKEFTV	0.120 Seq. ID No. 66
11	131	NILTIRLTA	0.080 Seq. ID No. 67
12	161	WITQCFLPV	0.080 Seq. ID No. 68
13	127	TVSGNILT	0.080 Seq. ID No. 69
14	153	LQQLSLLMW	0.080 Seq. ID No. 70
15	159	LMWITQCFL	0.060 Seq. ID No. 71
16	158	LLMWITQCF	0.060 Seq. ID No. 72
17	132	ILTIRLTAA	0.040 Seq. ID No. 73
18	148	SISSCLQQL	0.040 Seq. ID No. 74
19	128	VSGNILTIR	0.040
20	145	LQSISSCL	0.040 Seq. ID No. 75
21	135	IRLTAADHR	0.040
22	152	CLQQLSLLM	0.040 Seq. ID No. 76
23	110	AQDAPPLPV	0.040 Seq. ID No. 77
24	164	QCFLPVFLA	0.036 Seq. ID No. 78
25	143	RQLQSISS	0.024 Seq. ID No. 79
26	108	SLAQDAPPL	0.020 Seq. ID No. 80
27	73	NGCCRCGAR	0.020 Seq. ID No. 81
28	134	TIRLTAADH	0.020 Seq. ID No. 82
29	54	SGPGGGAPR	0.020
30	69	ASGLNGCCR	0.020 Seq. ID No. 83



- 44 -

Peptides were synthesized based on the peptide binding motif for HLA-A31 (hydrophobic residues at position 2 and positively charged residues at position 9) (Rammensee et al. 1995, Immunogenetics 41:178-228) and tested for reactivity with CTL clone 5.

5           These peptides were pulsed onto HLA-A31-positive 1510EBV B cells and tested for their ability to stimulate cytokine release by CTL clone 5. As shown in Table 6, the 10-mer peptide ESO10-53 (ASGPGGGAPR), starting at position 53 of the NY-ESO-1 protein was strongly recognized by CTL clone 5, while the overlapping 9-mer peptides, ESO9-54 as well as ESO10-127, were weakly recognized when pulsed  
10       onto 1510EBV B cells. CTL clone 10 recognized the same peptide as CTL clone 5 (data not shown). Interestingly, CTL clone 2 did not recognize any of these peptides (Table 6), even though it recognized 586mel and COS-7 transfected with NY-ESO-1 (see below). The reactivity of CTL clone 5 was undetectable when either the ESO9-54 or the ESO10-127 peptides were used at concentrations below 100 nM to sensitize  
15       EBV cells.

- 45 -

**Table 6**  
**Screening of synthetic peptides with reactivity to CTL Clone 5<sup>2</sup>**

Target cells pulsed with peptide		CTL clone 5
5	from NY-ESO-1	GM-CSF release (pg/ml)
<b>Peptides from CAG-3</b>		
	1510EBV + ESO9-90	AQPPSGQRR <50 (SEQ. ID NO: 6)
	1510EBV + ESO9-98	TPMEAEELAR <50 (SEQ. ID NO: 7)
10	1510EBV + ESO9-99	PMEAEELARR <50 (SEQ. ID NO: 8)
	1510EBV + ESO9-38	GATGGRGPR <50 (SEQ. ID NO: 9)
	1510EBV + ESO9-45	GPRGAGAAR <50 (SEQ. ID NO: 10)
	1510EBV + ESO9-89	LAQPPSGQR <50 (SEQ. ID NO: 11)
	1510EBV + ESO9-128	VSGNLTIR <50 (SEQ. ID NO: 12)
15	1510EBV + ESO9-35	IRLTAADHR <50 (SEQ. ID NO: 13)
	1510EBV - ESO9-54	SGPGGGAPR 304 (SEQ. ID NO: 14)
	1510EBV + ESO10-127	TVSGNLTIR 293 (SEQ. ID NO: 15)
	1510EBV + ESO10-34	TIRLTAADHR <50 (SEQ. ID NO: 16)
	1510EBV + ESO10-97	ATPMEAEELAR <50 (SEQ. ID NO: 17)
20	1510EBV + ESO10-170	FLAQPPSGQR <50 (SEQ. ID NO: 18)
	1510EBV + ESO10-98	TPMEAEELARR <50 (SEQ. ID NO: 19)
	1510EBV + ESO10-77	RCGARGPESR <50 (SEQ. ID NO: 20)
	1510EBV + ESO10-68	AASGLNGCCR <50 (SEQ. ID NO: 21)
	1510EBV + ESO10-171	LAQPPSGQRR <50 (SEQ. ID NO: 22)
25	1510EBV + ESO10-44	RGPRGAGAAR <50 (SEQ. ID NO: 23)
	1510EBV + ESO10-72	LNGCCRCGAR <50 (SEQ. ID NO: 24)
	1510EBV + ESO10-53	ASGPGGGAPR >2000 (SEQ. ID NO: 25)
	1510EBV + None	<50

- 46 -

<sup>1</sup>1510 EBV cells were incubated with individual peptide at a concentration of 0.1 µg/ml for 90 min. GM-CSF release was measured after co-incubation of peptide-loaded 1510EBV cells with CTL clone 5. GM-CSF release was measured after coincubation of peptide-loaded 1510 EBV cells with CTL clone 5. 1510EBV was a EBV transformed B cell line expressing HLA-A31.

### **Example 11**

#### **Recognition of Modified Peptides**

To examine whether CTL clone 5 also recognized peptides that contained the core amino acid sequence with the extension of amino acid residues at either the N or C terminus, we made overlapping 11-mer, 12-mer, 13-mer, 14-mer, and 15-mer peptides, as well as several peptides containing substitutions at either position 1, 2 or 10 of ESO10-53 (Table 7 and Figure 3A). CTL clone 5 was capable of recognizing 11-mer, 12-mer, 13-mer, 14-mer, and 15-mer peptides with amino acid extensions at the N terminus of the ESO-53 core peptide, although the longer peptides appeared to stimulate significantly less GM-CSF secretion than did the ESO10-53 10-mer peptide (Table 7). However, an extension of only a single amino acid residue at the C terminus of ESO10-53 abrogated its ability to stimulate T cells (Table 7). CTL clone 5 did not recognize the 8-mer peptide.

Titration experiments demonstrated that CTL reactivity was detectable at 10 nM concentration of ESO10-53 peptide. GM-CSF release from CTL clone 5 increased with the increasing peptide concentrations, and no plateau was reached at 10 µM peptide concentration (Fig. 5A). In addition to measuring cytokine release stimulated by ESO10-53, the ability of this peptide to sensitize target cells for lysis by CTL clone 5 was examined. CTL clone 5 was capable of lysing HLA-A31-positive tumor 586 mel, but not the HLA-A31-negative and NY-ESO-1-positive tumor 397mel (Fig. 5B). CTL clone 5 lysed > 60% of either 586EBV or 1510EBV that had been incubated with the ESO10-53 peptide at an E:T ratio of 40:1, and ~ 5-10% lysis of target cells was

- 47 -

observed at an E:T ratio of 2.5:1 E:T. CTL clone did not lyse either 586EBV or 1515EBV B cells alone or pulsed with an irrelevant peptide, nor did it lyse the HLA-A31-negative T2 cells pulsed with the ESO10-53 peptide (Fig. 5C).

Next, it was tested whether T cell recognition of the 10-mer peptide could be improved by substituting amino acids at anchor residues. A number of synthetic peptides with modification at residues 1, 2 and 10 were made and tested for recognition by CTL clone 5 when pulsed onto 586EBV B cells (Table 7). The modified 10-mer peptides with a substitution at position 2 derived from the wild-type ASGPGGGAPR were still recognized by CTL clone 5 when pulsed on 586EBV B cells. The reactivity of peptides containing a substitution of either Ala, Ile, Leu or Val at position 2 was lower than that of the wild-type peptide, while one peptide containing a substitution of Thr for Ser at position 2 resulted in a slightly higher reactivity than the wild-type ESO10-53 peptide. In contrast, peptides containing substitutions of Arg with Lys or His completely lost their ability to stimulate T cells, suggesting that the Arg at the C-terminus of the ESO10-53 peptide represents a critical anchor residue. Peptides with a substitution at position 1 were recognized poorly or not recognized at all by CTL clone 5 (Table 7). These results indicate that the ESO-53 peptide, ASGPGGGAPR, represents the best peptide for T cell recognition.

#### Example 12

##### **Antigenic Peptides Derived From An Alternative Open Reading Frame**

Two additional CTL clones, clones 2 and 14, appeared to recognize 586mel as well as COS-7 cells transfected with NY-ESO-1 and HLA-A31 cDNA, but failed to recognize the ESO 10-53 peptide (Fig. 6A-6H). CTL clone 5 and TIL1244 were used for the specificity controls. Additional experiments showed that CTL clone 2 did not respond to any of 19 other peptides containing the HLA-A31 binding motif derived from the normal open reading frame of NY-ESO-1 (Table 6). To test the hypothesis that CTL may recognize a peptide from a gene product translated from an alternative open reading frame of the same gene, synthetic peptides were made with HLA-A31

- 48 -

binding motif on the basis of amino acid sequence predicted from the second open reading frames (ORF2) (Fig. 3A). Strikingly, CTL clone 2 recognized ESORF2-9-19 (AAQERRVPR) as well as the overlapping ESORF2-10-18 (LAAQERRVPR) peptides when pulsed onto 1510EBV B cells. Representative data for CTL clone 2 is shown in Fig. 7A. CTL clone 14 recognized the same peptides as CTL clone 2 (Data not shown). These results suggest that CTL clones 2 and 14 recognized an antigenic peptide derived from the ORF2 (Fig. 3A). A protein database search revealed that the 58 amino acid protein of ORF2 has a 52% similarity to the chain A of glutamate dehydrogenase in a 25 amino acid region (34). Peptide titration experiments demonstrated that CTL clone 2 was capable of lysing 1510EBV pulsed with ESORF2-10-18 (LAAQERRVPR) at relatively low concentrations of peptide, but failed to lyse 1510EBV pulsed with ESO10-53 or HLA-A31-negative 1102EBV pulsed with ESORF2-10-18 (Fig. 7B). In addition, CTL clone 2 also recognized overlapping 11mer, 12-mer, and 13-mer peptides with amino acid extensions at the N terminus of the ESORF2-10-18 peptide at relatively high concentrations (data not shown).

Additional experiments were carried out to determine whether CTL clones recognize the ORF2 gene product of the NY-ESO-1 in other tumor types. As shown in Fig. 7C, the recognition pattern of CTL clone 2 was similar to that of CTL clone 5 on tumor cells. CTL clone 2 recognized HLA-A31 positive fresh 1315Br and 1295Br breast tumors as well as 586mel and 1388mel, but did not recognize HLA-A31 negative fresh 1411Br breast tumor, 397mel, nor the HLA-A31 negative 1295 fibroblast. Although 1353mel expresses HLA-A31, neither CTL clone 2 nor clone 5 responded to 1353mel because 1353mel is NY-ESO-1 negative tumor. As previously demonstrated, CTL clone 5 recognized the ESO10-53 ASGPGGGAPR peptide and CTL clone 2 recognized the ORF2-10-18 LAAQERRVPR peptide derived from the ORF2 following incubation with 1510EBV B cells (Fig. 7C). These results strongly suggest that the ORF2 gene product was translated, processed and presented in melanoma as well as breast tumors. Therefore, *NY-ESO-1* encodes two different

- 49 -

proteins: a protein with 180 amino acids (ORF1) recognized by CTL clones 5 and 10, and a protein with 58 amino acids (ORF2) recognized by CTL clones 2 and 14.

**Table 7**  
**Recognition of the modified peptides by CTL clone 5\***

Target cells pulsed with peptides	GM-CSF release by CTL clone 5	
	EXPT. 1 (1510EBV)	EXPT. 2 (586EBV)
1510EBV + AGAARASGPGGGAPR	728	532 (SEQ. ID NO: 26)
1510EBV + GAARASGPGGGAPR	659	678 (SEQ. ID NO: 27)
1510EBV + AARASGPGGGAPR	844	738 (SEQ. ID NO: 28)
1510EBV + ARASGPGGGAPR	840	738 (SEQ. ID NO: 29)
1510EBV + RASGPGGGAPR	851	708 (SEQ. ID NO: 30)
1510EBV + SGPGGGAPR	<50	<50 (SEQ. ID NO: 14)
1510EBV + GPGGGAPR	<50	<50 (SEQ. ID NO: 31)
1510EBV + ASGPGGGAPRG	<50	<50 (SEQ. ID NO: 32)
1510EBV + SGPGGGAPRG	<50	<50 (SEQ. ID NO: 33)
1510EBV + <u>ASGPGGGAPR</u>	1097	1044 (SEQ. ID NO: 25)
1510EBV + AAGPGGGAPR	688	676 (SEQ. ID NO: 34)
1510EBV + AIGPGGGAPR	428	550 (SEQ. ID NO: 35)
1510EBV + ALPGGGAPR	200	378 (SEQ. ID NO: 36)
1510EBV + AVPGGGAPR	556	512 (SEQ. ID NO: 37)
1510EBV + ATGPGGGAPR	1630	1158 (SEQ. ID NO: 38)
1510EBV + ASGPGGGAP <b>K</b>	<50	<50 (SEQ. ID NO: 39)
1510EBV + ASGPGGGAP <b>H</b>	<50	<50 (SEQ. ID NO: 40)
1510EBV + <b>T</b> SGPGGGAPR	320	346 (SEQ. ID NO: 41)
1510EBV + <b>V</b> SGPGGGAPR	825	666 (SEQ. ID NO: 42)
1510EBV + <b>L</b> SGPGGGAPR	<50	<50 (SEQ. ID NO: 43)
1510EBV + <b>R</b> SGPGGGAPR	<50	<50 (SEQ. ID NO: 44)
1510EBV + None	<50	<50

\*586EBV or 1510EBV cells were incubated with individual peptide at a concentration of 0.1µg/ml for 90 min. GM-CSF release was measured after coinoculation of peptide-loaded EBV cells with 5 x 10<sup>4</sup> CTL clone 5. The wild-type 10 mer ESO10-53 peptide was underlined. Peptides with amino acid substitutions are marked by bold face and underscored. 586EBV and 1510EBV were HLA-A31-positive EBV transformed B cell lines.

052226:061300

- 51 -

**Example 13***In vivo* Treatment Assay

For *in vivo* treatment, MHL-A31<sup>+</sup> transgenic mice are challenged with either  $1 \times 10^5$  or  $5 \times 10^5$  CAG-3 B16 mouse melanoma cells intravenously in order to establish pulmonary metastases. Mice are subsequently vaccinated with a recombinant virus expressing cancer peptide, SEQ. ID NO. 4 or 5 at  $10^5$  PFU/mg body weight. Mice are euthanized on day 12 and the number of pulmonary metastases in vaccinated mice vs. non-vaccinated mice determined.

**Example 14**Cancer Antigen Specific T LymphocytesImmunotherapy

T-lymphocytes presensitized to a melanoma antigen may be effective in therapeutically treating mammals afflicted with a melanoma. T-lymphocytes are isolated from peripheral blood or melanoma tumor suspensions and cultured *in vitro* (Kawakami et al 1988, J. Exp. Med. 168:2183-2191).

The T lymphocytes are exposed to the cancer peptide, SEQ. ID NO. 4 or 5 at a concentration of  $1 \mu\text{g/ml}$  alone or in the presence of IL-2, resensitized and expanded in culture. T-lymphocytes exposed to the cancer peptide are administered to a mammal at about  $10^9$  to  $10^{12}$  lymphocytes per mammal. The lymphocytes are administered either intravenously, intraperitoneally or intralesionally. The treatment may be administered concurrently with other therapeutic treatments such as cytokines, surgical excision of melanoma lesions and chemotherapeutic drugs.

**DISCUSSION**

## NY-ESO-1 Is A Cellular Immune Target

Five differentiation antigens including tyrosinase, MART-1, gp 100, TRP-1/gp75 and TRP-2 have been identified as melanoma Ags recognized by T cells derived from TILs (13-19), which have been shown to be associated with antitumor reactivity *in vivo*. Thus far, no TILs available in the Surgery Branch at National



Cancer Institute recognize MAGE-1, BAGE and GAGE, which are expressed only in testis and cancer cells. Here we show that NY-ESO-1, another cancer-shared Ag, is a tumor Ag recognized by HLA-A31-restricted T cells. NY-ESO-1 was independently isolated using the autologous serum from a patient with esophageal cancer (29),

5 suggesting that the NY-ESO-1 gene product was an immune target for Ab-mediated immunity. Results in this study provide evidence that NY-ESO-1 is also an immune target recognized by T cells. This is further supported by a recent report that HLA-A2 restricted CTL recognize NY-ESO-1 established in a melanoma patient (35). Several tumor antigens, including MAGE-1, tyrosinase, TRP-1, recognized by CTL, have been  
10 found to be reactive with antibody as well (36, 37). Since NY-ESO-1 is not expressed in normal human tissues except the testis, which does not express MHC class I molecules and is considered as an immunologically privileged site, this gene product may constitute a safe immune target for the immunotherapy of patients with cancer.  
NY-ESO-1 Is A Breast Cancer Ag

15 Based on its gene expression pattern, NY-ESO-1 belongs to a member of an expanding family of antigens (Ags) including MAGE-1, MAGE-3, BAGE, GAGE and HOM-MEL-40 (9-12, 30). However, NY-ESO-1 is highly expressed in a significant proportion of breast, prostate and bladder cancers (29) compared to MAGE, BAGE and GAGE. More importantly, CTL clones recognized two HLA-A31-positive fresh  
20 and cultured breast cancer cells (Table 2 and Fig. 7C). To our knowledge, this is the first demonstration of CTL recognition of NY-ESO-1 positive breast cancer cells. Although the expression of MAGE-1, MAGE-3 and others were reported to be detected by RT-PCR in breast tumors at a low frequency (<5-10%), CTL recognition of these breast tumors by the Ag-specific CTL has not been documented. It has been  
25 difficult to generate breast-reactive CTLs from PBL *in vitro* although MHC-restricted T cells that recognized HER-2/neu peptides on breast cancer cells have been reported (26-28). Identification of NY-ESO-1 peptides presented on the cell surface of breast cancers is important for the development of Ag-specific cancer vaccines for the

- 53 -

treatment of patients with breast cancer. The CTL cloning approach described here represents a strategy for the isolation breast cancer Ags.

#### Translation of Different ORFs As A Mechanism For Generating T Cell Epitopes

To define antigenic peptides, we found the 10-mer ASGPGGGAPR derived  
5 from the NY-ESO-1 protein as the best antigenic peptide recognized by CTL clone 5 although the 9-mer, 11-mer, 12-mer, 13-mer, 14-mer and 15-mer peptides were also recognized. This reactivity may be due to the presence of two proline residues in these peptides. Proline residues in the core peptide sequence may allow the peptides to bulge out of the MHC binding pocket, thus the anchored residues in the longer  
10 peptides can still fit into the HLA-A31 molecule. An alternative explanation is that the longer peptides may be processed to the shorter peptides by extracellular or serum proteases (38). However, when the longer peptides were pulsed onto 586EBV B cells in serum-free conditions, they were still recognized by CTL clone 5 (data not shown). This experiment, however, does not exclude the possibility that these longer peptides  
15 were processed by extracellular proteases. The modified peptide, ATGPGGGAPR, with a substitution of Thr for Ser appeared to slightly improve T cell recognition. It has been shown that modified peptides could improve binding affinity to the MHC class I molecule, thus enhancing the immunogenicity of peptides (39). It is not clear why CTL clone 5 recognized the unrelated ESO10-127 peptide, but its recognition was  
20 weak and only could be detected at a relatively high peptide concentration.

Interestingly, two additional CTL clones recognized COS-7 transfected with NY-ESO-1 plus HLA-A31 cDNA, but not the ESO10-53 peptide which was derived from the ORF1 of the NY-ESO-1 gene (Fig. 6A-6D). Further analysis showed that CTL clone 2 recognized a peptide from the gene product translated from an alternative  
25 open reading frame (ORF2) of NY-ESO-1. Although there are several examples that two different proteins are translated from different ORFs from a single viral mRNA (40), very few cases have been reported in single eukaryotic mRNA. Two examples have been reported: TRP-1/gp75 which encodes two different proteins, gp75

recognized by sera from a patient with melanoma and a 24 amino acid gene product recognized by CTLs (24, 37); and 43 kDa-Ag recognized by squamous cell carcinoma reactive CTL (41). Interestingly, the cyclin-dependent kinase inhibitor p16 gene also encodes two gene products, p16 and p19<sup>ARF</sup>. However, the alternative ORF gene product p19<sup>ARF</sup> is translated from an alternatively spliced transcript shares an identical sequence with the p16 transcript except the first exon (42). Recent studies showed that the alternative reading frame product p19<sup>ARF</sup> plays a role in cell cycle regulation and tumor suppression (43). The NY-ESO-1 gene reported here encodes two different proteins: a 180 amino acid protein encoded by ORF1 and a 58 amino acid protein encoded by ORF2. The ORF2 product is located inside ORF1. Strikingly, CTL clones 5 and 10 recognized antigenic peptides derived from ORF1, while CTL clone 2 and 14 recognized an antigenic peptide from ORF2. Both CTL clones 2 and 5 recognized several HLA-A31<sup>+</sup> melanomas as well as fresh breast tumors (Table 2 and Fig. 7C), suggesting that the translation of the alternative ORF2 may serve as a general mechanism *in vivo* for generating T cell epitopes.

The mechanism by which the alternative ORF is translated is currently not known. However, there are several potential explanations for the production of alternative reading frames. The leaky-scanning model is one possible explanation: ribosomes occasionally bypass the first AUG with a poor KOZAK consensus sequence and initiates translation at a downstream AUG (43, 44). In the case of NY-ESO-1, the start codon for translation of ORF1 is not in the optimal context. There are four potential start codons that could be used to translate the ORF2. In our previous report, a CTL epitope was translated from an alternative reading frame of gp75/TRP-1 (24). Recognition of the epitope of ORF3 by CTL was affected by the presence of the first ATG codon used for the translation of the gp75 protein and was completely abolished when the internal ATG preceeding the T cell epitope (ORF3P) was changed to ATC, suggesting that ribosomal scanning may be a possible mechanism. In the studies of the influenza nucleoprotein, CTL epitopes were produced via a ribosomal scanning

mechanism (44). However, in a similar study, ribosomal frameshifting was suggested as a mechanism for the production of T cell epitopes (45). Other mechanisms have also been proposed for the production of T cell epitopes derived from different genes. For example, several T cell epitopes were identified from gene products translated from a cryptic initiation codon of the 5' untranslated region (46,47), from a non-ATG-defined open reading frame (48), and from introns of transcript (22, 49, 50). Since both the alternative open reading frame of *gp75/TRP-1* and *NY-ESO-1* are located within the primary open reading frame, it is of particular interest to understand the underlying mechanism.

Although there are only a few examples of the usage of the alternative open reading frames in eukaryotes reported in the literature, we believe that more examples will be reported in the future when tumor-reactive CTL and autoantibodies are available and used to identify target proteins or peptides. Therefore, it is important to understand the biologic significance of the gene products translated from alternative open reading frames. One possibility is that these gene products serve as antigenic targets of the Ag processing machinery to increase the efficiency and capacity of the immune surveillance. Identification of T cell epitopes derived from different open reading frames of NY-ESO-1 suggests that the identity of immunogenic peptides for cancer vaccines may not be limited only to peptides derived from the primary open reading frame. It is not clear at the present time whether the ORF2 gene product of NY-ESO-1 and the ORF3 gene product of *gp75/TRP-1* have biologic functions in addition to immune responses of T cells.

- 56 -

## References

1. Rosenberg, S.A., B.S. Packard, P.M. Aebersold, D. Solomon, S.L. Topalian, S.T. Toy, P. Simon, M.T. Lotze, J.C. Yang, C.A. Seipp, et al, 1998. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N. Engl. J. Med. 319:1676.
2. Rosenberg, S.A., J.Y. Yannelli and J.C. Yang, 1994. Treatment of Patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and interleukin-2. J. Natl. Cancer Inst. 86:1159.
3. Boon, T., J.C. Cerottini, B. Van den Eynde, P. van der Bruggen and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337.
4. Houghton, A.N. 1994. Commentary: cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1.
5. Tsomides, T.J. and H.N. Eisen, 1994. Commentary: T-cell antigens in cancer. Proc. Natl. Acad. Sci. USA 91:3487.
6. Pardoll, D.M. 1994. News and views: a new look for the 1990s. Nature 369:357.
7. Wang, R.F., and S.A. Rosenberg, 1996. Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. J. Leukocyte Biol. 60:296.
8. Rosenberg, S.A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18:175.
9. van der Bruggen, P., C. Traversari, Pl. Chomez, C. Lurquin, E. Deplaen, B. Van den Eynde, A. Knuth and T. Boon, 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643.

10. Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J.J. Gaforio, E. De Plaen, B. Lethe, F. Brasseur and T. Boon, 1994. Human gene MAGE-3 codes for an antigen recognized o a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179:921.
- 5 11. Van Den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas and T. Boon, 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182:689.
12. Boël P., C. Wildmann, M.L. Sensi, R. Brasseur, J.C. Renauld, P. Coulie, T. Boon and P. van der Bruggen, 1995. BAGE: a new gene encoding an  
10 antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167.
13. Kawakami, Y., S. Eliyahu, C.H. Delgardo, P.F. Robbins, L. Rivoltini, S.L. Topalian, T. Miki and S.A. Rosenberg, 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells  
15 infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91:3515.
14. Coulie, P.G., V. Brichard, A. Van Pel, T. Wolfe, J. Schneider, C. Traversari, S. Mattei, E.D. De Plaen, C. Lurquin, J.P. Szikora, J.C. Reauld and T. Boon, 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35.
- 20 15. Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robins, K. Sakaguchi, E. Appella, J.R. Yannelli, G.J. Adema, T. Miki and S.A. Rosenberg, 1994. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
- 25 16. Brichard, V., A. Van Pel, T. Wölfel, E. De Plaen, B. Lethé, P. Coulie and T. Boon, 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178:489.

17. Robbins, P.F., M. El-Gamil, Y. Kawakami, E. Stevens, J. Yanneli and S.A. Rosenberg, 1994. Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 54:3124.
18. Wang, R.F., P.F. Robbins, Y. Kawakami, X.Q. Kang and S.A. Rosenberg, 1995. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181:799.
19. Wang, R.F., E. Appella, Y. Kawakami, X.Q. Kang and S.A. Rosenberg, 1995. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184:2207.
20. Wolfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wolfel, E. Klehmann-Hieb, E. De Plaen, T. Hankeln, K.H. Meyer Zum Buschenfeld and D. Beach, 1995. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281.
21. Robbins, P.F., M. El-Gamil, Y.F. Li, Y. Kawakami, D. Loftus, E. Appella and S.A. Rosenberg, 1996. A mutated  $\beta$ -catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183:1185.
22. Coulie, P.G., F. Lehmann, B. Lethe, J. Herman, C. Lurquin, M. Andrawiss and T. Boon, 1995. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA 92:7976.
23. Mandruzzato, S., F. Brasseur, G. Andry, T. Boon and P. van der Bruggen, 1997. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 186:785.
24. Wang, R.F., M.R. Parkhurst, Y. Kawakami, P.F. Robbins and S.A. Rosenberg, 1996. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 183:1131.

25. Bloom, M.D., D. Perry-Lalley, P.F. Robbins, Y. Li, M. El-Gamil, S.A. Rosenberg and J.C. Yand, 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185:453.
26. Disis, M.L., J.W. Smith, A.E. Murphy, W. Chen and M.A. Cheever, 1994. In vitro generation of human cytotoxic T-cells specific for peptides derived from the HER-2/new protooncogene protein. Cancer Res. 54:1071.
27. Fisk, B., B. Chesak, J.S. Pollack, J.T. Wharton and C.G. Ioannides, 1994. Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/Neu proto-oncogene in vitro. Cell Immunol. 157:415.
28. Peoples, G.E., I. Yosino, C.C. Douville, J.V.R. Andrews, P.S. Goedegebuure and T.J. Eberlein, 1994. TCR V $\beta$ 3<sup>+</sup> and V $\beta$ 6<sup>+</sup> CTL recognized tumor-associated antigens related to HER-2/neu expression in HLA-A2<sup>+</sup> ovarian cancers. J. Immunol. 152:4993.
29. Chen Y.-T., M.J. Scanlan, U. Sahin, O. Tureci, A.O. Gure, S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh and L.J. Old, 1997. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94:1914.
30. Topalian, S., D. Solomon, F.P. Avis, A.E. Chang, D.L. Freeksen, W.M. Linehan, M.T. Lotze, C.N. Robertson, C.A. Seipp, P. Simon, C.G. Simpson and S.A. Rosenberg, 1988. Immunotherapy of patients with advanced cancer using tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study, J. Clin. Oncol. 6:839.
31. Wang, R.F., S. Johnston, S. Southwood, A. Sette and S.A. Rosenberg, 1998. Recognition of an antigenic peptide derived from TRP-2 by cytotoxic T lymphocytes in the context of HLA-A31 and -A33. J. Immunol. 160:890.
32. Riddell, S.R. and P.D. Greenberg, 1995. Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 13:545.



33. Rammensee, H.G., T. Friede and S. Stevanović, 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178.
34. Baker, P.J., K.L. Britton, P.C. Engel, G.W. Farrants, K.S. Lilley, D.W. Rice and T.J. Stillman, 1992. Subunit assembly and active site location in the structure of glutamate dehydrogenase. Proteins 12:75.
35. Jager, E., Y.-T. Chen, J.W. Drijfout, J. Karbach, M. Ringhoffer, D. Jager, M. Arand, H. Wada, Y. Noguchi, E. Stockert, L.J. Old and A. Knuth, 1998. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187:265.
36. Sahin, U., O. Tureci, H. Schmitt, B. Cochlovius, T. Johannes, R. Schmits, F. Stenner, G. Luo, I. Schobert and M. Pfreundschuh, 1995. Human neoplasms elicit multiple immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 92:11810.
37. Mattes, J.J., T.M. Thomson, L.J. Old and K.O. Lloyd, 1983. A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum. Int. J. Cancer 32:717.
38. Kozłowski, S., M. Corr, M. Shirai, L.F. Boyd, C.D. Pendleton, J.A. Berzofsky and D.H. Margulies, 1993. Multiple pathways are involved in the extracellular processing of MHC class I-restricted peptides. J. Immunol. 151:4033.
39. Parkhurst, M.R., M. Salgaller, S. Southwood, P. Robbins, A. Sette, S.A. Rosenberg and Y. Kawakami, 1996. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A0201 binding residues. J. Immunol. 157:2539.
40. Fischer, F., D. Peng, S.T. Hingley, S.R. Weiss and P.S. Masters, 1997. The internal open reading frame within the nucleocapsid gene of mouse hepatitis virus encodes a structural protein that is not essential for viral replication. J. Virol. 71:996.

41. Quelle, D.E., F. Zindy, R.A. Ashmun and C.J. Sherr, 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993.
42. Kamijo, T., F. Zindy, M.F. Roussel, D.E. Quelle, J.R. Downing,  
5 R.A. Ashmun, G. Grosveld and C.J. Sheer, 1997. tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19<sup>ARF</sup>. Cell 91:649.
43. Kozak, M. 1994. Determinants of translational fidelity and efficiency in vertebrate mRNAs. Biochimie 76:815.
44. Bullock, T.N.J. and L.C. Eisenlohr, 1996. ribosomal scanning  
10 past the primary initiation codon as a mechanism for expression of CTL epitopes encoded in alternative reading frames. J. Exp. Med. 184:1319.
45. Elliott, T., H. Bodmer and A. Townsend, 1996. Recognition of out-of-frame major histocompatibility complex class I-restricted epitopes in vivo. Eur. J. Immunol. 26:1175.
- 15 46. Uenaka, A., T. Ono, T. Akisawa, H. Wada, T. Yasuda and E. Nakayama, 1994. Identification of a unique peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the aki onogene. J. Exp. Med. 180:1599.
47. Shastri, N., V. Nguyen and F. Gonzalez, 1995. Major  
20 histocompatibility class I molecules can present cryptic translation products to T cells. J. Biol. Chem. 270:1088.
48. Malarkannan, S., M. Afkarian and N. Shastri, 1995. A rare cryptic translation product is presented by K<sup>b</sup> major histocompatibility complex class I molecule to alloreactive T cells. J. Exp. Med. 182:1739.
- 25 49. Guilloux, Y., L. Lucas, V.G. Brichard, A. Van Pel, C. Viret, E. De Plaen, F. Brasseur, B. Lethe, F. Jotereau and T. Boon, 1996. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V. gene. J. Exp. Med. 183:1173.

- 62 -

50. Robbins, P.F., M. El-Gamil, Y.F. Li, E. Fitzgerald, Y. Kawakami and S.A. Rosenberg, 1997. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. *J. Immunol.* 159:303.

HARSH

- 63/1 -

## WE CLAIM:

2. A cancer peptide, functional portion or derivative wherein the peptide is encoded by a nucleic acid sequence consisting of a portion of SEQ. ID NO: 2, wherein said portion encodes a peptide immunologically recognized by antigen specific cytotoxic T lymphocytes.
3. A cancer peptide, functional portion or derivative thereof wherein the peptide is encoded by a nucleic acid sequence consisting of SEQ. ID NO: 3 or portion thereof.
4. A cancer peptide consisting of a portion of SEQ. ID NO: 4 or derivative thereof, wherein said portion is immunologically recognized by antigen specific cytotoxic T lymphocytes.
5. A cancer peptide consisting of SEQ. ID NO: 5 or portion or derivative thereof.
6. A cancer peptide, portion or derivative thereof according to claim 2-4 or 5 wherein the cancer peptide is immunologically recognized by HLA restricted cytotoxic T lymphocytes.
7. A cancer peptide, portion or derivative thereof according to claim 2-4 or 5 wherein the cytotoxic T lymphocytes are MHC class I restricted.
8. A cancer peptide, portion or derivative thereof according to claim 2-6 or 7 wherein the cancer peptide is derived from a cancer selected from the group consisting of: a non-Hodgkins lymphoma, leukemia, Hodgkins lymphoma, lung cancer, liver cancer, metastases, melanoma, adenocarcinoma, thymoma, colon cancer, uterine cancer, breast cancer, prostate cancer, ovarian cancer, cervical cancer, bladder cancer, kidney cancer, pancreatic cancer and sarcoma.
9. A cancer peptide, portion or derivative thereof according to claim 2-7 or 8 wherein the cancer peptide or portion thereof is present on primary breast tumor isolates and melanoma cells.
10. A cancer peptide, portion or derivative thereof according to claim 2 wherein the peptide is encoded by a nucleic acid sequence consisting of SEQ. ID NO: 51.

AMENDED SHEET

WO 99/18206

PCT/US98/19609

AA134

- 64/1 -

11. A cancer peptide, portion or derivative thereof according to claim 2 wherein the cancer peptide consists of the amino acid sequence:

ASGPGGGAPR (SEQ. ID NO. 25), or derivative thereof.

12. A cancer peptide according to claim 11, further consisting of an addition of 1 to about 10 amino acids at the N-terminus of SEQ. ID NO: 25.

13. A cancer peptide according to claim 11, further consisting of an addition of 1 to about 5 amino acids at the N-terminus of SEQ. ID NO: 25.

14. The cancer peptide, portion or derivative thereof according to claim 2 wherein the cancer peptide consists of the amino acid sequence:

ASGPGGGAPK (SEQ. ID NO: 39).

15. The cancer peptide, portion or derivative thereof according to claim 2 wherein the cancer peptide consists of the amino acid sequence:

AGAARASGPGGGAPR (SEQ. ID NO: 26)

16. The cancer peptide, portion or derivative thereof according to claim 2 wherein the cancer peptide consists of the amino acid sequence:

RGPRGAGAARASGPGGGAPR (SEQ. ID NO: 45).

17. A cancer peptide, portion or derivative thereof according to claim 2 wherein the cancer peptide consists of the amino acid sequence:

TVSGNLTIR (SEQ. ID NO: 15).

18. A cancer peptide or analog thereof consisting of the amino acid sequence:

Xaa<sub>1</sub>Xaa<sub>2</sub>Xaa<sub>3</sub>GPGGGAPXaa<sub>4</sub>, wherein Xaa<sub>1</sub> is no amino acid or one to 10 amino acids, Xaa<sub>2</sub> is Ala, Thr, Val, Leu or Arg, Xaa<sub>3</sub> is Ser or a conservative amino acid substitution, and Xaa<sub>4</sub> is Arg or Lys.

19. The cancer peptide according to claim 18 wherein the conservative amino acid at Xaa<sub>3</sub> is selected from the group consisting of Ala, Val, Ile, Leu and Thr.

ORIGINAL OF TWO

WO 99/18206

PCT/US98/19609

HBT/31

- 65/1 -

20. The cancer peptide according to claim 18 wherein Xaa<sub>1</sub> is at least one amino acid selected from the group consisting of Ala, Gly, Arg or combinations thereof.

21. The cancer peptide according to claim 18 wherein Xaa<sub>2</sub> is Ala, Val or Thr.

22. The cancer peptide according to claim 18 wherein Xaa<sub>2</sub> is Arg.

23. The cancer peptide according to claim 18 wherein Xaa<sub>2</sub> is Arg and Xaa<sub>1</sub> is one to 5 amino acids selected from the group consisting of Ala, Gly, Arg or combinations thereof.

24. A cancer peptide, portion or derivative thereof encoded by an alternative open reading frame consisting of SEQ. ID NO. 3, variant or homolog thereof

26. A cancer peptide, portion or derivative thereof according to claim 24 wherein the peptide comprises the amino acid sequence:

LAAQERRVPR (SEQ. ID NO: 47).

27. A cancer peptide, portion or derivative thereof according to claim 24 wherein the peptide comprises the amino acid sequence:

AAQERRVPR (SEQ. ID NO: 46).

28. A pharmaceutical composition comprising at least one cancer peptide according to claims 2-24, 26 or 27 and a pharmaceutically acceptable carrier.

29. A pharmaceutical composition consisting essentially of a peptide having a portion of SEQ. ID NO. 4, said portion is immunologically recognized by antigen specific cytotoxic T lymphocytes, a peptide having SEQ. ID NO: 5, SEQ. ID NO: 14, SEQ. ID NO: 25, SEQ. ID NOS: 34-38, 41, 42, 46, 47 or combinations thereof and a pharmaceutically acceptable carrier.

30. A immunogen comprising the cancer peptide according to claims 2-24, 26 or 27 alone or in combination with at least one immunostimulatory molecule, said immunogen elicits antigen specific cytotoxic T lymphocytes.

31. A immunogen according to claim 30 wherein the

WO 99/18206

PCT/US98/19609

AKT/34

- 66/1 -

immunostimulatory molecule is an HLA molecule.

32. An isolated nucleic acid sequence consisting of a portion of SEQ ID NO: 2, or homolog thereof, wherein said portion encodes a peptide immunologically recognized by antigen specific cytotoxic T lymphocytes.

33. An isolated nucleic acid sequence consisting of SEQ ID NO.: 3 or portion or variant thereof.

34. An isolated nucleic acid sequence according to claim 33 wherein the nucleic acid sequence encodes an alternative open reading frame gene product.

35. An isolated nucleic acid sequence according to claim 32 wherein the sequence encodes an amino acid sequence:

ASGPGGGAPR (SEQ ID NO.: 25), or derivative thereof.

36. An isolated nucleic acid sequence encoding the ORF2 peptide of SEQ. ID NO: 5.

37. An isolated nucleic acid sequence according to claim 36 wherein the nucleic acid sequence encodes a cancer peptide having the amino acid sequence:

LAAQERRVPR (SEQ. ID NO: 47).

38. An isolated nucleic acid sequence according to claim 36 wherein the nucleic acid sequence encodes a cancer peptide having the amino acid sequence:

AAQERRVPR (SEQ. ID NO: 46).

39. A recombinant expression vector comprising the nucleic acid sequence according to claims 32-37 or 38.

40. A host organism transformed or transfected with a recombinant expression vector according to claim 39.

41. A host organism according to claim 40 wherein the host organism is an antigen presenting cell.

AMENDED SHEET

AA34

- 67/1 -

42. An oligonucleotide consisting of a nucleic acid sequence complementary to the nucleic acid sequence according to claims 32-37 or 38.

43. A recombinant virus comprising a recombinant virus which has incorporated into a viral genome or portion thereof the nucleic acid sequence according to claims 32-37 or 38.

44. A recombinant virus according to claim 43 further comprising at least one gene encoding an immunostimulatory molecule

45. The recombinant virus according to claim 43 wherein the virus is selected from the group consisting of retrovirus, baculovirus, Ankara virus, fowlpox, adenovirus, and vaccinia virus.

46. The recombinant virus according to claim 43 wherein the cancer peptide is derived from melanocytes.

47. A recombinant virus according to claim 44 wherein the immunostimulatory molecule is a HLA class I molecule.

48. A host organism transformed or transfected with the recombinant virus according to claim 43-46 or 47.

49. An isolated antibody or antigen binding portion thereof that binds the cancer peptide, or portion thereof encoded by SEQ. ID NO: 3.

51. An isolated antibody that binds a cancer antigen consisting of SEQ ID NOS: 5, 6, 14, 25, 34-38, 41, 42, 46, 47 or a fragment thereof.

52. An isolated antibody that binds the cancer peptide, antigen or variant thereof of claim 11.

53. A method of producing a recombinant cancer peptide or portion thereof comprising:

- a. inserting a nucleotide sequence of SEQ ID NO.: 3



WO 99/18206

PCT/US98/19609

AA134

- 68/1 -

or portion or variant thereof, or a portion or variant of SEQ ID NO. 2, into an expression vector;

- b. transferring the expression vector into a host cell;
- c. culturing the host cell under conditions appropriate for expression of the cancer peptide or portion thereof; and
- d. harvesting the recombinant cancer peptide, or portion thereof.

54. A method according to claim 53 further comprising in step (a) inserting a nucleotide sequence encoding an HLA class I molecule, or portion thereof into the expression vector.

55. A method of detecting the presence of cancer or precancer in a mammal comprising:

- a. contacting a nucleic acid sequence of SEQ ID NO.: 3 or portion or variant thereof, or a portion of SEQ ID NO. 2 with a test biological sample of mRNA taken from the mammal under conditions allowing for a complex to form between the sequence and the mRNA;
- b. detecting the complex;
- c. comparing the amount of mRNA in the test sample with an amount of mRNA from a known normal biological sample, wherein an increased amount of mRNA from the test sample is indicative of cancer or precancer.

56. A method according to claim 55 wherein the cancer or precancer is melanoma.

57. A method according to claim 55 wherein the biological sample is from breast tissue.

58. A method of detecting an CAG-3 genomic nucleic acid sequence in a biological sample comprising:

- a. contacting the genomic nucleic acid sequence with SEQ

WO 99/18206

PCT/US98/19609 #14 31

- 69/1 -

ID NO.: 3, 51, or portion or variant thereof under conditions to allow complexes to form between the genomic nucleic acid sequence; and

b. detecting the complex.

59. A method of detecting the cancer peptide or portion thereof according to claims 2-24, 26 or 27 in a biological sample comprising:

- a. contacting the sample with antibodies specific for said cancer peptide under conditions to form an immune complex, and
- b. detecting the presence of the immune complex.

60. A method of preventing or inhibiting cancer in a mammal comprising: administering to the mammal an effective amount of the cancer peptide, or portion thereof according to claims 2-24, 26 or 27, alone or in combination with an HLA molecule, said amount is effective in preventing or inhibiting the cancer in the mammal

61. A method of inhibiting melanoma in a mammal comprising:

- a. exposing T lymphocytes *in vitro* to a cancer peptide, tumor antigen or portion thereof according to claims 2-24, 26 or 27, alone or in combination with an MHC molecule for a time sufficient to elicit cancer peptide specific T lymphocytes;
- b. administering the cancer peptide specific T lymphocytes to the mammal in an amount sufficient to inhibit the melanoma.

62. A method of preventing or inhibiting cancer in a mammal comprising administering to the mammal an effective amount of the cancer peptide according to claims 2-24, 26 or 27 alone, or in combination with an HLA molecule, said amount is effective in preventing or inhibiting cancer in a mammal.

AMENDED SHEET

WO 99/18206

PCT/US98/19609

Aft 34

- 70/1 -

63. A method of preventing or inhibiting cancer in a mammal comprising administering to the mammal an effective amount of a recombinant virus according to claims 43-46 or 47 alone or in combination with an exogenous immunostimulatory molecule said amount is effective in preventing or inhibiting the cancer.

64. A method according to claim 63 wherein the mammal expresses an HLA Class I molecule selected from the group consisting of HLA-A31, HLA-A3, HLA-A11, HLA-A33, or HLA-A68.

65. A pharmaceutical composition comprising the recombinant virus according to claims 43-46 or 47 alone or in combination with an exogenous immunostimulatory molecule, chemotherapy drug, antibiotic, antifungal drug, antiviral drug or combination thereof and a pharmaceutically acceptable carrier.

66. A transgenic animal carrying and expressing a gene consisting of SEQ ID NO: 3 or portion thereof, or a portion of SEQ ID NO. 2, wherein said portion encodes a peptide immunologically recognized by antigen specific cytotoxic T lymphocytes

67. A cancer antigen specific human cytotoxic T lymphocyte elicited by the cancer peptide according to claim 2-24, 26 or 27.

68. The cancer antigen specific human cytotoxic T lymphocyte according to claim 67, wherein the lymphocyte recognizes an HLA-A31 molecule.

69. The cancer antigen specific human cytotoxic T lymphocyte according to claim 67; wherein the lymphocyte recognizes an HLA Class I molecule selected from the group consisting of HLA-A3, HLA-A11, HLA-A33, and HLA-A68.

AMENDED SHEET

1 / 16




FIG. IA




FIG. IB

2 / 16




FIG. 1C




FIG. 2

3 / 16

SEQ ID NO:1 AGCAGGGGGCGCTGTGTGTACCGAGAATACGAGAATACCTCGTGGGCCCTGACCTT

SEQ ID NO:2

CTCTCTGAGAGCCGGGCAGAGGCTCCGGAGCCATGCAGGCCGAAGGCCGGGGCACA

(SEQ ID NO:4)ORF1► M Q A E G R G T  
SEQ ID NO:3

GGGGGTTTCGACGGGCGATGCTGATGGCCCAGGAGGCCCTGGCATTCTGATGGCCC

ORF1► G G S T G D A D G P G G P G I P D G P

(SEQ ID NO:5)ORF2► M L M A Q E A L A F L M A

AGGGGGCAATGCTGGCGGCCAGGAGAGGGCGGTGCCACGGGCGGCAGAGGTCCCC

ORF1► G G N A G G P G E A G A T G G R G P

ORF2► Q G A M L A A Q E R R V P R A A E V P

GGGGCGCAGGGGCAGCAAGGGCCTCGGGGCCGGGAGGAGCGCCCCGCGGGGTCCG

ORF1► R G A G A A R A S G P G G G A P R G P

ORF2► G A Q G Q Q G P R G R E E A P R G V R

CATGGCGGCGGGCTTCAGGGCTGAATGGATGCTGCAGATGCGGGGCCAGGGGGCC

ORF1► H G G A A S G L N G C C R C G A R G P

ORF2► M A A R L Q G

FIG. 3A-1

4 / 16

GGAGAGCCGCCTGCTTGAGTTCTACCTCGCCATGCCTTTTCGCACACCCATGGAAG

ORF1▶ E S R L L E F Y L A M P F A T P M E

CAGAGCTGGCCCCGAGGAGCCTGGCCCAGGATGCCCCACCGCTTCCCGTGCCAGGG

ORF1▶ A E L A R R S L A Q D A P P L P V P G

GTGCTTCTGAAGGAGTTCACTGTGTCCGGCAACATACTGACTATCCGACTCACTGC

ORF1▶ V L L K E F T V S G N I L T I R L T A

TGCAGACCACCGCCAACCTGCAGCTCTCCATCAGCTCCTGTCTCCAGCAGCTTTCCC

ORF1▶ A D H R Q L Q L S I S S C L Q Q L S

TGTTGATGTGGATCACGCAGTGCTTTCTGCCCGTGTTTTTGGGTCAGCCTCCCTCA

ORF1▶ L L M W I T Q C F L P V F L A Q P P S

GGGCAGAGGCGCTAAGCCCAGCCTGGCGCCCTTCCTAGGTGCATGCCTCCTCCCCT

ORF1▶ G Q R R

AGGGAATGGTCCCAGCACGAGTGGCCAGTTCATTGTGGGGGCCTGATTGTTTGTGCG

CTGGAGGAGGACGGCTTACATGTTTGTTCGTAGAAAATAAACTGAGCTACGAA

AAAAAAAAAAAAAAAAAAAAA

FIG. 3A-2

5 / 16

SEQ ID NO:60 ENT F. coli 894 QAAATGGDARQLVGVLVQSGL-PDTSAL--QAQLRETLPPHMPVWLLQ 941  
 SEQ ID NO:57 + A G +R L YL P++ + L + PP VP VLI+  
 SEQ ID NO:55 ESO-ORF1 77 RCGARGPESRLLEFYIAM-PFATMEAEALA--RRSLAQDAPPLP'PGVLLKKEFTVSGNITLTPL 137  
 SEQ ID NO:58 + G GP + LLEF L M P+ T + LA R SLA A LP+ +L E ++ G + +L  
 SEQ ID NO:61 TEGU HSV11 604 OAGVAGPAAALLEFTLNMLPMKTA'VGDFLASTRLSLADVA'AHLP'VOHVLDENSLIGRLALAKL 667  
 SEQ ID NO:56 ESO-ORF2 1 MIMQAEALAFIMAGGAMLAQERRV 25  
 SEQ ID NO:59 M EAL FLN Q M+ A + V  
 SEQ ID NO:62 GDH C.symb 348 MPTTNEALRFILMQPNNVAPSKAV 372

FIG. 3B



6 / 16




FIG. 4

7 / 16




FIG. 5A

8 / 16




FIG. 5B

9 / 16




FIG. 5C

10 / 16




FIG. 6A




FIG. 6B

11 / 16




FIG. 6C




FIG. 6D

12 / 16




FIG. 6E




FIG. 6F

13 / 16




FIG. 6G




FIG. 6H



14 / 16




FIG. 7A

15 / 16




FIG. 7B

16 / 16




FIG. 7C

**COMBINED DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, the information given herein is true, that I believe I am the original, first and sole (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: NOVEL HUMAN CANCER ANTIGEN NY ESO-1/CAG-3 AND GENE ENCODING SAME

which is described in: ☐ PCT International Application No. \_\_\_\_\_, filed

☐ the attached application; or ☒ the specification in application U.S. Serial No. 09/529,206, filed on to be assigned, and amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information known to me which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56 (a).

I hereby claim foreign priority benefits under Title 35 United States Code, § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign applications(s) for patent or inventor's certificate or any PCT international applications(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Country	Application	Date of Filing (Day, Month Year)	Priority Claimed Under 35 USC § 119
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional patent application(s).

Provisional Application Serial No.	Filing Date	Status: patented, pending, abandoned
60/061,428	08 October 1997	Abandoned

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s) or PCT International application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application.

Application Serial No.	Filing Date	Status: patented, pending, abandoned
PCT/US98/19609	21 September 1998	published

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

James C. Haight, Reg. No. 25,588; Robert Benson, Reg. No. 33,612; Jack Spiegel, Reg. No. 34,477; Susan S. Rucker, Reg. No. 35,762; David R. Sadowski, Reg. No. 32,808; Steven M. Ferguson, Reg. No. 38,448; Stephen L. Finley, Reg. No. 36,357; John P. Kim, Reg. No. 38,514 and Joseph K. Hemby, Jr., Reg. No. 42,652, all of the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852 USA.

I further direct that all correspondence concerning this application be directed to:

Office of Technology Transfer  
National Institutes of Health  
6011 Executive Boulevard, Suite 325  
Rockville, MD 20852  
Telephone: (301) 496-7056  
Fax: (301) 402-0220

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of first joint inventor Rong Fu WANG

Inventor's signature: *Rong Fu Wang*

Date: 6/2/00

Country of Citizenship: United States of America

Residence: 4949 Battery Lane #409, Bethesda, Maryland 20814, US

Post Office Address: 4949 Battery Lane #409, Bethesda, Maryland 20814, US

Full Name of second joint inventor Steven ROSENBERG

Inventor's signature: *Steven Rosenberg*

Date: 5/31/00

Country of Citizenship: United States of America

Residence: 10104 Iron Gate Road, Potomac, Maryland 20854, US

Post Office Address: 10104 Iron Gate Road, Potomac, Maryland 20854, US